data_2mi6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mi6 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.473 HG21 ' O ' ' A' ' 30' ' ' SER . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.487 ' CG1' HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.461 HG11 ' HA ' ' A' ' 23' ' ' ALA . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.455 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.481 ' HA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.556 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.537 ' CD2' ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.487 HD11 ' CG1' ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' HG21 ' A' ' 11' ' ' VAL . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.468 HG23 ' CD1' ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.429 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.42 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.484 ' HG ' ' N ' ' A' ' 40' ' ' LYS . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.493 ' CG2' HD12 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.471 HG13 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.434 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.501 HG23 ' N ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.501 ' N ' HG23 ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.471 ' O ' HG13 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.513 HG21 ' N ' ' A' ' 53' ' ' GLU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.513 ' N ' HG21 ' A' ' 52' ' ' VAL . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.493 HD12 ' CG2' ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.47 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.47 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.463 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.455 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.433 ' OXT' HG22 ' A' ' 62' ' ' ILE . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.496 HG13 ' N ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.451 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.43 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.48 ' HB3' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.542 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.456 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.485 ' CG2' HD13 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.416 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.518 ' HG ' ' N ' ' A' ' 40' ' ' LYS . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.527 ' N ' ' O ' ' A' ' 31' ' ' GLU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.501 HG23 ' CD1' ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.464 ' CG1' ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.464 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 40' ' ' LYS . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.501 ' CD1' HG23 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.464 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.464 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 59' ' ' VAL . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.514 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 12' ' ' GLY . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.475 ' N ' HG11 ' A' ' 11' ' ' VAL . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.452 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.468 ' HA ' HD13 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.571 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.533 ' CD2' ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.425 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.495 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.552 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.405 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.552 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.521 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.473 ' CG1' HD23 ' A' ' 39' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 51' ' ' PRO . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.475 ' N ' ' O ' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.526 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.544 ' HA ' ' CD2' ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.41 ' CG1' HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.425 ' O ' ' O ' ' A' ' 39' ' ' LEU . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.468 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.405 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.452 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.514 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.447 HG23 HD12 ' A' ' 62' ' ' ILE . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.466 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.466 ' HA ' HD11 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.565 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.582 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 6.1 t30 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.507 ' HG3' ' ND2' ' A' ' 33' ' ' ASN . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.582 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.486 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.416 ' CG2' ' CD1' ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.477 HD13 ' HB3' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 43' ' ' VAL . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.482 HG22 HD12 ' A' ' 45' ' ' ILE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.435 ' O ' ' N ' ' A' ' 45' ' ' ILE . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.439 ' O ' HG11 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.477 ' HB3' HD13 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.404 HG23 ' C ' ' A' ' 51' ' ' PRO . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 39' ' ' LEU . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 5.6 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.466 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HD11 ' A' ' 62' ' ' ILE . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.301 0.572 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.497 HG13 ' N ' ' A' ' 12' ' ' GLY . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.497 ' N ' HG13 ' A' ' 11' ' ' VAL . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.45 ' OG1' ' CD1' ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.463 ' HA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.56 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' HB ' ' A' ' 41' ' ' VAL . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.467 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' HG12 ' A' ' 11' ' ' VAL . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.544 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.441 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.401 ' OE1' ' ND2' ' A' ' 33' ' ' ASN . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.544 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.55 ' CD2' ' HA ' ' A' ' 51' ' ' PRO . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' ARG . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.469 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.542 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.55 ' HA ' ' CD2' ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.479 HG22 ' N ' ' A' ' 53' ' ' GLU . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 52' ' ' VAL . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.447 HD23 ' HB3' ' A' ' 58' ' ' GLN . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.463 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.434 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.442 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.458 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.45 ' CD1' ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.525 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.428 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 18' ' ' MET . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.455 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.466 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.556 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.54 ' CD2' ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.454 ' HB2' HD13 ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.432 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.526 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.3 OUTLIER -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.526 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.483 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.519 ' CG2' HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.498 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.519 ' CG1' ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.513 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.513 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.519 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.418 HG13 HD12 ' A' ' 54' ' ' LEU . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.438 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.519 HD13 ' CG2' ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.47 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.47 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.455 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.525 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.4 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.435 HG13 ' HA ' ' A' ' 23' ' ' ALA . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.44 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.464 ' HB3' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.558 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.542 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.428 ' HB2' ' HB ' ' A' ' 41' ' ' VAL . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.531 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.546 ' CG2' ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.435 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.622 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.531 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.486 ' CG2' HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 43' ' ' VAL . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.567 HG23 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.567 ' CD1' HG23 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.472 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.503 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.416 HG11 ' N ' ' A' ' 53' ' ' GLU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.464 ' C ' ' CD1' ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.486 HD13 ' CG2' ' A' ' 41' ' ' VAL . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.455 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.622 ' CD1' ' CD1' ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.455 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.403 HG13 ' C ' ' A' ' 58' ' ' GLN . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.44 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.459 HD13 HG23 ' A' ' 62' ' ' ILE . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.416 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 85.9 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.458 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.473 ' HA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.566 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CD2' ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.541 ' CB ' HG23 ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.438 ' C ' HG21 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.515 ' N ' HG21 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.447 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG2' HD11 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 39.6 t-20 -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.513 HD11 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.482 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.541 HG23 ' CB ' ' A' ' 27' ' ' ALA . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.503 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.503 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.524 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.405 HG23 ' C ' ' A' ' 51' ' ' PRO . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.445 ' C ' ' CD1' ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.461 ' O ' ' O ' ' A' ' 39' ' ' LEU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.46 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.46 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.458 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.449 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 81.1 m-85 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.321 0.581 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.417 ' HB3' HD11 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.426 HG13 ' C ' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.414 ' HE2' ' HB3' ' A' ' 18' ' ' MET . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . 0.468 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.521 ' HA ' ' CD1' ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.549 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.521 ' CD1' ' HA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.576 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 47.6 t-20 -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.576 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.507 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.524 ' CG2' HG12 ' A' ' 52' ' ' VAL . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.423 ' O ' HG12 ' A' ' 43' ' ' VAL . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.421 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.507 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.424 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.479 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.479 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.527 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 14' ' ' SER . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.414 ' N ' ' HG3' ' A' ' 13' ' ' GLU . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.474 ' HA ' HD11 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.523 ' C ' ' CG2' ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.536 ' O ' ' CD2' ' A' ' 25' ' ' LEU . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.541 ' CB ' HG22 ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.441 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.46 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.535 ' O ' ' N ' ' A' ' 40' ' ' LYS . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.558 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.43 ' N ' ' O ' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.558 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' GLU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.541 HG22 ' CB ' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.449 ' CG1' ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.449 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.424 HG11 HG13 ' A' ' 41' ' ' VAL . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.416 HG12 ' C ' ' A' ' 58' ' ' GLN . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.449 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.527 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ILE . . . . . 0.424 HG21 ' OXT' ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -122.41 94.09 48.03 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.161 . . . . 0.0 109.454 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.27 146.33 56.75 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.708 2.272 . . . . 0.0 111.749 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.0 t -110.63 139.21 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.487 HG23 ' N ' ' A' ' 6' ' ' GLU . 15.2 m -59.63 -35.95 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.524 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.487 ' N ' HG23 ' A' ' 5' ' ' VAL . 82.5 tt0 -108.05 129.65 55.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.498 ' O ' ' CG2' ' A' ' 7' ' ' VAL . 7.4 p -132.64 33.51 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.274 -0.891 . . . . 0.0 109.427 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -119.29 136.1 54.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.9 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 -102.68 149.21 24.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.323 -0.86 . . . . 0.0 109.487 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.473 HG21 ' O ' ' A' ' 30' ' ' SER . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.487 ' CG1' HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.461 HG11 ' HA ' ' A' ' 23' ' ' ALA . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.455 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.481 ' HA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.556 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.537 ' CD2' ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.487 HD11 ' CG1' ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' HG21 ' A' ' 11' ' ' VAL . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.468 HG23 ' CD1' ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.429 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.42 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.429 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.484 ' HG ' ' N ' ' A' ' 40' ' ' LYS . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.493 ' CG2' HD12 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.471 HG13 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.434 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.501 HG23 ' N ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.501 ' N ' HG23 ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.471 ' O ' HG13 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.513 HG21 ' N ' ' A' ' 53' ' ' GLU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.513 ' N ' HG21 ' A' ' 52' ' ' VAL . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.493 HD12 ' CG2' ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.47 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.47 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.463 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.455 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.433 ' OXT' HG22 ' A' ' 62' ' ' ILE . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . 0.501 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.7 OUTLIER -45.05 -57.97 6.34 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 179.983 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HD2' ' N ' ' A' ' 2' ' ' ARG . 51.6 Cg_endo -72.07 136.16 26.59 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.728 2.285 . . . . 0.0 111.792 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.405 ' C ' HG22 ' A' ' 5' ' ' VAL . 13.3 m -113.46 34.0 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.156 -0.965 . . . . 0.0 109.545 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.405 HG22 ' C ' ' A' ' 4' ' ' VAL . 52.9 t -140.85 153.68 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -61.59 146.19 49.67 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.285 -0.884 . . . . 0.0 109.556 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.07 140.02 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.964 . . . . 0.0 109.457 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -133.91 162.89 30.79 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.216 -0.928 . . . . 0.0 109.489 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -105.28 160.0 15.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.496 HG13 ' N ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.451 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.43 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.48 ' HB3' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.542 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.456 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.527 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.485 ' CG2' HD13 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.416 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.518 ' HG ' ' N ' ' A' ' 40' ' ' LYS . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.527 ' N ' ' O ' ' A' ' 31' ' ' GLU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.501 HG23 ' CD1' ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.464 ' CG1' ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.464 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.466 ' HA ' ' HA ' ' A' ' 40' ' ' LYS . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.501 ' CD1' HG23 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.464 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.464 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 59' ' ' VAL . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -125.15 80.99 63.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.228 -1.16 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.19 136.3 31.53 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.637 2.225 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.2 p -135.17 143.44 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.568 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.8 m -116.27 11.32 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.934 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.91 137.58 57.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.198 -0.939 . . . . 0.0 109.458 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 7' ' ' VAL . 54.1 t -81.95 5.04 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.239 -0.913 . . . . 0.0 109.56 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -115.38 133.45 56.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.444 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.514 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 -96.82 169.88 9.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.287 -0.883 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 12' ' ' GLY . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.475 ' N ' HG11 ' A' ' 11' ' ' VAL . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.452 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.468 ' HA ' HD13 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.571 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.533 ' CD2' ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.425 ' HB3' ' HB ' ' A' ' 41' ' ' VAL . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.495 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.552 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.405 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.552 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.521 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.473 ' CG1' HD23 ' A' ' 39' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 51' ' ' PRO . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.475 ' N ' ' O ' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.526 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.544 ' HA ' ' CD2' ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.41 ' CG1' HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.425 ' O ' ' O ' ' A' ' 39' ' ' LEU . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.468 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.405 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.468 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.452 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.514 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.447 HG23 HD12 ' A' ' 62' ' ' ILE . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 53.44 68.3 3.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.255 -1.144 . . . . 0.0 109.436 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.83 150.05 67.26 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.743 2.295 . . . . 0.0 111.771 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.9 t -110.18 136.46 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.312 -0.867 . . . . 0.0 109.422 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.3 m -131.03 162.72 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.89 . . . . 0.0 109.514 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -86.6 148.32 25.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.6 t -104.94 124.46 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.272 -0.893 . . . . 0.0 109.466 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -134.1 160.52 37.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 -102.23 148.92 24.85 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.477 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.466 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.466 ' HA ' HD11 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.565 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.474 ' O ' ' N ' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.582 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 6.1 t30 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.507 ' HG3' ' ND2' ' A' ' 33' ' ' ASN . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.582 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.486 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.416 ' CG2' ' CD1' ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.477 HD13 ' HB3' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 43' ' ' VAL . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.482 HG22 HD12 ' A' ' 45' ' ' ILE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.435 ' O ' ' N ' ' A' ' 45' ' ' ILE . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.439 ' O ' HG11 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.477 ' HB3' HD13 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.404 HG23 ' C ' ' A' ' 51' ' ' PRO . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.437 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.447 ' O ' ' O ' ' A' ' 39' ' ' LEU . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 5.6 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.466 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.433 HG21 HD11 ' A' ' 62' ' ' ILE . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.84 160.42 44.73 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.256 -1.143 . . . . 0.0 109.534 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.19 145.07 53.62 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.724 2.283 . . . . 0.0 111.768 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.5 m -128.52 161.27 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.288 -0.883 . . . . 0.0 109.486 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 5' ' ' VAL . 19.5 m -130.02 144.5 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.6 mt-10 -57.07 -46.07 82.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.211 -0.93 . . . . 0.0 109.432 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.428 ' O ' ' CG2' ' A' ' 7' ' ' VAL . 2.7 p 178.35 71.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.489 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . 93.9 m-20 -113.96 135.44 53.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.544 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -109.81 144.36 38.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.497 HG13 ' N ' ' A' ' 12' ' ' GLY . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.497 ' N ' HG13 ' A' ' 11' ' ' VAL . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.442 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.45 ' OG1' ' CD1' ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.463 ' HA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.56 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.539 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' HB ' ' A' ' 41' ' ' VAL . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.467 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' HG12 ' A' ' 11' ' ' VAL . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.544 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.441 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.401 ' OE1' ' ND2' ' A' ' 33' ' ' ASN . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.441 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.544 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.55 ' CD2' ' HA ' ' A' ' 51' ' ' PRO . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 48' ' ' ARG . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.469 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.542 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.55 ' HA ' ' CD2' ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.479 HG22 ' N ' ' A' ' 53' ' ' GLU . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 52' ' ' VAL . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.447 HD23 ' HB3' ' A' ' 58' ' ' GLN . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.463 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.434 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.442 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.458 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' NZ ' ' O ' ' A' ' 8' ' ' ASP . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.45 ' CD1' ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 53.46 66.86 4.16 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.251 -1.146 . . . . 0.0 109.416 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.91 149.38 65.86 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.724 2.283 . . . . 0.0 111.782 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 38.7 t -108.63 135.39 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.433 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -117.96 135.94 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.26 153.72 29.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.444 ' O ' HG21 ' A' ' 7' ' ' VAL . 29.4 m -68.29 128.79 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.386 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -113.5 149.3 34.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.508 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.525 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 -113.34 147.01 38.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.315 -0.866 . . . . 0.0 109.412 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.428 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.418 HG13 ' N ' ' A' ' 18' ' ' MET . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.455 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.466 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.556 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.54 ' CD2' ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.454 ' HB2' HD13 ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.432 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.526 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.3 OUTLIER -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.526 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.483 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.519 ' CG2' HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.498 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.519 ' CG1' ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.513 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.413 ' N ' HG22 ' A' ' 45' ' ' ILE . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.513 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.519 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.418 HG13 HD12 ' A' ' 54' ' ' LEU . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.438 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.519 HD13 ' CG2' ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.47 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.47 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.455 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.525 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . 0.442 ' HB3' ' HD2' ' A' ' 3' ' ' PRO . 16.5 mmt180 -125.31 161.69 48.52 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.208 -1.172 . . . . 0.0 109.503 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.442 ' HD2' ' HB3' ' A' ' 2' ' ' ARG . 50.3 Cg_endo -70.46 145.1 52.21 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.752 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 40.2 t -115.1 133.11 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 5' ' ' VAL . 20.2 m -131.95 139.79 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.481 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -118.82 137.96 53.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.49 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.02 133.84 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -109.44 138.38 45.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.467 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.4 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 -110.93 155.2 23.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.435 HG13 ' HA ' ' A' ' 23' ' ' ALA . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.44 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.464 ' HB3' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.558 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.542 ' CD2' ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.428 ' HB2' ' HB ' ' A' ' 41' ' ' VAL . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.443 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.531 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.546 ' CG2' ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.435 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.622 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.531 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.486 ' CG2' HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.503 ' O ' HG12 ' A' ' 43' ' ' VAL . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.567 HG23 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.567 ' CD1' HG23 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.472 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.503 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.416 HG11 ' N ' ' A' ' 53' ' ' GLU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.464 ' C ' ' CD1' ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.486 HD13 ' CG2' ' A' ' 41' ' ' VAL . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.455 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.622 ' CD1' ' CD1' ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.455 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.403 HG13 ' C ' ' A' ' 58' ' ' GLN . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.44 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.459 HD13 HG23 ' A' ' 62' ' ' ILE . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 2' ' ' ARG . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . 0.477 ' HB3' ' HD3' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -44.46 -59.76 3.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.257 -1.143 . . . . 0.0 109.511 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HD3' ' HB3' ' A' ' 2' ' ' ARG . 52.1 Cg_endo -72.21 129.97 15.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.717 2.278 . . . . 0.0 111.75 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 42.1 t -130.96 141.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -0.844 . . . . 0.0 109.499 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 m -126.64 154.11 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.25 -0.906 . . . . 0.0 109.47 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.409 ' HB2' ' O ' ' A' ' 9' ' ' TYR . 95.3 mt-10 -57.19 138.13 55.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -0.929 . . . . 0.0 109.529 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.413 HG11 ' O ' ' A' ' 7' ' ' VAL . 23.0 t -87.77 -11.93 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.85 . . . . 0.0 109.507 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.489 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . 91.9 m-20 -92.8 -72.16 0.61 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.416 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 85.9 m-85 -124.34 148.64 47.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.409 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.413 ' HB ' ' O ' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.458 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.473 ' HA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.566 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.538 ' CD2' ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.541 ' CB ' HG23 ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.438 ' C ' HG21 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.515 ' N ' HG21 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.447 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG2' HD11 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 39.6 t-20 -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.513 HD11 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.482 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.541 HG23 ' CB ' ' A' ' 27' ' ' ALA . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.503 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.503 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.524 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.405 HG23 ' C ' ' A' ' 51' ' ' PRO . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.445 ' C ' ' CD1' ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.461 ' O ' ' O ' ' A' ' 39' ' ' LEU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.46 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.46 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.458 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' NZ ' ' O ' ' A' ' 8' ' ' ASP . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . 0.502 ' CB ' ' CD ' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -44.09 -61.23 2.14 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.502 ' CD ' ' CB ' ' A' ' 2' ' ' ARG . 51.3 Cg_endo -71.51 129.46 15.79 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.75 2.3 . . . . 0.0 111.84 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -139.84 153.16 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 7' ' ' VAL . 23.6 t -105.81 121.77 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.561 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -48.55 -29.05 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.164 -0.96 . . . . 0.0 109.409 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 5' ' ' VAL . 9.8 t -115.01 157.45 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.893 . . . . 0.0 109.508 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.416 ' N ' HG12 ' A' ' 7' ' ' VAL . 92.5 m-20 -90.3 -34.16 15.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.455 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.449 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 81.1 m-85 -142.82 153.63 43.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.243 -0.911 . . . . 0.0 109.518 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.417 ' HB3' HD11 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.426 HG13 ' C ' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.414 ' HE2' ' HB3' ' A' ' 18' ' ' MET . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . 0.468 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.521 ' HA ' ' CD1' ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.549 ' CB ' ' O ' ' A' ' 23' ' ' ALA . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.521 ' CD1' ' HA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.576 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 47.6 t-20 -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.576 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.507 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.524 ' CG2' HG12 ' A' ' 52' ' ' VAL . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.423 ' O ' HG12 ' A' ' 43' ' ' VAL . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.421 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.507 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.524 HG12 ' CG2' ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.424 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.479 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.479 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.411 ' HE2' ' O ' ' A' ' 8' ' ' ASP . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 38.0 mtp180 -123.96 78.0 58.36 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.267 -1.137 . . . . 0.0 109.522 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.0 150.11 66.31 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.655 2.237 . . . . 0.0 111.843 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.428 ' O ' ' CG1' ' A' ' 7' ' ' VAL . 39.3 t -104.82 139.37 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.222 -0.924 . . . . 0.0 109.461 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 p -78.9 -22.45 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -0.862 . . . . 0.0 109.564 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . 0.414 ' HA ' ' NZ ' ' A' ' 61' ' ' LYS . 36.9 mt-10 -61.16 -34.35 74.88 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.428 ' CG1' ' O ' ' A' ' 4' ' ' VAL . 12.7 p -58.05 -25.33 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.446 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -115.68 131.86 56.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.25 -0.907 . . . . 0.0 109.479 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.527 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 -107.75 159.71 16.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.291 -0.88 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.414 ' HG3' ' N ' ' A' ' 14' ' ' SER . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.414 ' N ' ' HG3' ' A' ' 13' ' ' GLU . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.449 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.474 ' HA ' HD11 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.523 ' C ' ' CG2' ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.536 ' O ' ' CD2' ' A' ' 25' ' ' LEU . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LEU . . . . . 0.536 ' CD2' ' O ' ' A' ' 24' ' ' THR . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.541 ' CB ' HG22 ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.441 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 9' ' ' TYR . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.46 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.535 ' O ' ' N ' ' A' ' 40' ' ' LYS . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.558 ' CG2' ' CD1' ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.43 ' N ' ' O ' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.558 ' CD1' ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.535 ' N ' ' O ' ' A' ' 31' ' ' GLU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.541 HG22 ' CB ' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.449 ' CG1' ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.514 ' N ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.449 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.424 HG11 HG13 ' A' ' 41' ' ' VAL . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.479 ' O ' ' O ' ' A' ' 39' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.416 HG12 ' C ' ' A' ' 58' ' ' GLN . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.449 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.527 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ILE . . . . . 0.424 HG21 ' OXT' ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.653 HG11 HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.465 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.658 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.731 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.653 HD11 HG11 ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.728 HG23 HD12 ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.453 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.44 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.453 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 32' ' ' VAL . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.913 HG22 HD13 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.602 HD12 ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.01 HG12 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.461 ' O ' ' C ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' C ' ' O ' ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.01 ' O ' HG12 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.602 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.692 HG22 HD11 ' A' ' 54' ' ' LEU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.844 ' C ' HD12 ' A' ' 54' ' ' LEU . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.913 HD13 HG22 ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.483 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.483 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.465 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.52 HG12 ' HA ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.436 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.703 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.743 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.743 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.47 HG12 HD21 ' A' ' 39' ' ' LEU . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 HD12 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.431 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.431 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.063 HD12 HG23 ' A' ' 32' ' ' VAL . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.851 HG22 HD13 ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.621 HD12 ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.007 HG12 ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.007 ' O ' HG12 ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.621 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.544 ' C ' HD12 ' A' ' 54' ' ' LEU . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.851 HD13 HG22 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.517 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.44 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.457 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.667 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.741 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.741 HD23 ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.63 HG12 HD21 ' A' ' 39' ' ' LEU . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.077 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.41 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.077 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.795 HG22 HD13 ' A' ' 54' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 1.031 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.045 HG12 ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.045 ' O ' HG12 ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.869 ' HA ' HD22 ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.502 HG12 HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.703 ' C ' HD12 ' A' ' 54' ' ' LEU . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.795 HD13 HG22 ' A' ' 41' ' ' VAL . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.466 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.41 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.457 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.517 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.492 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.618 ' CA ' HD12 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.745 ' O ' HD23 ' A' ' 25' ' ' LEU . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.534 HD13 ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.086 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 2.3 t-20 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.406 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.086 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.493 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.788 HG22 HD12 ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.626 HD12 ' CA ' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.955 HG12 ' O ' ' A' ' 50' ' ' THR . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.463 ' O ' ' C ' ' A' ' 46' ' ' PHE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.955 ' O ' HG12 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.626 ' CA ' HD12 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.446 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 HG22 ' A' ' 41' ' ' VAL . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.48 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.406 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.48 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 20.4 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.301 0.572 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.785 ' OG1' HD11 ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.521 HG12 ' HA ' ' A' ' 23' ' ' ALA . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.681 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.746 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.746 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.427 ' O ' ' N ' ' A' ' 42' ' ' LEU . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.738 HG12 HD21 ' A' ' 39' ' ' LEU . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.072 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.403 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.462 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.072 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 1.004 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.021 HG12 ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' O ' ' C ' ' A' ' 46' ' ' PHE . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.021 ' O ' HG12 ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.795 ' HA ' HD22 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.419 HG13 HG23 ' A' ' 41' ' ' VAL . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.535 ' C ' HD12 ' A' ' 54' ' ' LEU . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.542 HD13 HG22 ' A' ' 41' ' ' VAL . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.472 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.468 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.785 HD11 ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.438 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.436 HG12 ' HA ' ' A' ' 23' ' ' ALA . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.476 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.471 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.661 ' CA ' HD12 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.74 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.492 HG12 HD21 ' A' ' 39' ' ' LEU . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.467 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.044 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 16.8 t-20 -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.41 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.044 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.984 HG22 HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.716 HD22 ' HB3' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.024 HG12 ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.482 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.024 ' O ' HG12 ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.716 ' HB3' HD22 ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.787 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.984 HD13 HG22 ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.476 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.531 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.418 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.46 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.64 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.75 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.529 HG12 HG12 ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.443 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.063 ' CD2' HG23 ' A' ' 32' ' ' VAL . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.541 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.681 HG22 HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.044 HG12 ' O ' ' A' ' 50' ' ' THR . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.638 HG22 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.638 ' CD1' HG22 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.478 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.044 ' O ' HG12 ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.501 HG12 HD11 ' A' ' 54' ' ' LEU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.942 ' C ' HD12 ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.942 HD12 ' C ' ' A' ' 53' ' ' GLU . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.462 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.874 ' CE1' HD11 ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.462 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.46 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.416 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CE1' HG23 ' A' ' 59' ' ' VAL . 85.9 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.462 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.737 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.575 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.574 ' C ' HG23 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.576 ' N ' HG23 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.478 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.4 OUTLIER -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.033 HD12 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.576 HG23 ' N ' ' A' ' 29' ' ' ILE . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.82 HD22 ' HB3' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.053 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.48 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.519 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . 1.053 ' O ' HG12 ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.82 ' HB3' HD22 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.788 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 ' C ' ' A' ' 53' ' ' GLU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.471 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.471 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.459 HG23 ' CE1' ' A' ' 9' ' ' TYR . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.652 HG22 ' O ' ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.555 ' HB3' HD13 ' A' ' 29' ' ' ILE . 81.1 m-85 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.321 0.581 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.415 ' HB3' HD12 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.717 HG11 ' HB2' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.784 ' CA ' HD12 ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.723 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.784 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.555 HD13 ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.116 ' CG2' HD12 ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.6 OUTLIER -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.116 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.516 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.642 HG22 HD12 ' A' ' 54' ' ' LEU . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.524 HD12 ' CA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.945 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.945 ' O ' HG12 ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.524 ' CA ' HD12 ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.559 HG13 HG23 ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.432 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.642 HD12 HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.489 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.489 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.547 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' HB3' ' A' ' 27' ' ' ALA . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 22' ' ' PHE . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' MET . . . . . 0.471 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.756 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.79 ' C ' HG23 ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.79 HG23 ' C ' ' A' ' 23' ' ' ALA . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LEU . . . . . 0.756 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.61 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.55 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.562 ' N ' HG23 ' A' ' 41' ' ' VAL . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 30' ' ' SER . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.095 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.416 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 1.095 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.61 ' CG2' ' HB1' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.651 HD12 ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.969 HG12 ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.969 ' O ' HG12 ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.651 ' HA ' HD12 ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.498 ' HA ' HD23 ' A' ' 54' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.471 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.547 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ILE . . . . . 0.503 HG22 ' OXT' ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -122.41 94.09 48.03 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.161 . . . . 0.0 109.454 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.27 146.33 56.75 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.708 2.272 . . . . 0.0 111.749 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.534 HG12 ' H ' ' A' ' 6' ' ' GLU . 41.0 t -110.63 139.21 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.427 HG23 ' N ' ' A' ' 6' ' ' GLU . 15.2 m -59.63 -35.95 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.524 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.534 ' H ' HG12 ' A' ' 4' ' ' VAL . 82.5 tt0 -108.05 129.65 55.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.77 ' O ' HG22 ' A' ' 7' ' ' VAL . 7.4 p -132.64 33.51 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.274 -0.891 . . . . 0.0 109.427 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -119.29 136.1 54.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.9 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 -102.68 149.21 24.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.323 -0.86 . . . . 0.0 109.487 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.653 HG11 HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.465 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.658 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.731 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.653 HD11 HG11 ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.728 HG23 HD12 ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.453 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.44 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.453 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 32' ' ' VAL . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.913 HG22 HD13 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.602 HD12 ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.01 HG12 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.461 ' O ' ' C ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' C ' ' O ' ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.01 ' O ' HG12 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.602 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.692 HG22 HD11 ' A' ' 54' ' ' LEU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.844 ' C ' HD12 ' A' ' 54' ' ' LEU . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.913 HD13 HG22 ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.483 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.483 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.465 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.52 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.7 OUTLIER -45.05 -57.97 6.34 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 179.983 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.52 ' HD2' ' N ' ' A' ' 2' ' ' ARG . 51.6 Cg_endo -72.07 136.16 26.59 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.728 2.285 . . . . 0.0 111.792 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -113.46 34.0 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.156 -0.965 . . . . 0.0 109.545 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 52.9 t -140.85 153.68 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.512 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -61.59 146.19 49.67 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.285 -0.884 . . . . 0.0 109.556 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.07 140.02 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.964 . . . . 0.0 109.457 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -133.91 162.89 30.79 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.216 -0.928 . . . . 0.0 109.489 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -105.28 160.0 15.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.52 HG12 ' HA ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.436 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.703 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.743 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.743 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.47 HG12 HD21 ' A' ' 39' ' ' LEU . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 HD12 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.431 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.431 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.063 HD12 HG23 ' A' ' 32' ' ' VAL . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.851 HG22 HD13 ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.621 HD12 ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.007 HG12 ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.007 ' O ' HG12 ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.621 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.544 ' C ' HD12 ' A' ' 54' ' ' LEU . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.851 HD13 HG22 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -125.15 80.99 63.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.228 -1.16 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.19 136.3 31.53 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.637 2.225 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.738 HG22 ' H ' ' A' ' 6' ' ' GLU . 12.2 p -135.17 143.44 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.568 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.8 m -116.27 11.32 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.934 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.738 ' H ' HG22 ' A' ' 4' ' ' VAL . 97.1 mt-10 -64.91 137.58 57.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.198 -0.939 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.688 HG12 ' O ' ' A' ' 7' ' ' VAL . 54.1 t -81.95 5.04 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.239 -0.913 . . . . 0.0 109.56 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -115.38 133.45 56.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.444 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.517 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 -96.82 169.88 9.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.287 -0.883 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.44 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.457 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.667 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.741 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.741 HD23 ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.63 HG12 HD21 ' A' ' 39' ' ' LEU . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.077 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.077 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.795 HG22 HD13 ' A' ' 54' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 1.031 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.045 HG12 ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.045 ' O ' HG12 ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.869 ' HA ' HD22 ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.502 HG12 HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.703 ' C ' HD12 ' A' ' 54' ' ' LEU . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.795 HD13 HG22 ' A' ' 41' ' ' VAL . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.466 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.41 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.457 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.517 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 53.44 68.3 3.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.255 -1.144 . . . . 0.0 109.436 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.83 150.05 67.26 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.743 2.295 . . . . 0.0 111.771 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.9 t -110.18 136.46 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.312 -0.867 . . . . 0.0 109.422 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.3 m -131.03 162.72 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.89 . . . . 0.0 109.514 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -86.6 148.32 25.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.6 t -104.94 124.46 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.272 -0.893 . . . . 0.0 109.466 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -134.1 160.52 37.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 -102.23 148.92 24.85 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.477 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.492 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.618 ' CA ' HD12 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.745 ' O ' HD23 ' A' ' 25' ' ' LEU . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.534 HD13 ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.086 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 2.3 t-20 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.406 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.086 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.493 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.788 HG22 HD12 ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.626 HD12 ' CA ' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.955 HG12 ' O ' ' A' ' 50' ' ' THR . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.463 ' O ' ' C ' ' A' ' 46' ' ' PHE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.955 ' O ' HG12 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.626 ' CA ' HD12 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.446 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 HG22 ' A' ' 41' ' ' VAL . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.48 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.406 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.48 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 20.4 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.84 160.42 44.73 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.256 -1.143 . . . . 0.0 109.534 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.19 145.07 53.62 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.724 2.283 . . . . 0.0 111.768 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.5 m -128.52 161.27 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.288 -0.883 . . . . 0.0 109.486 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.5 m -130.02 144.5 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.6 mt-10 -57.07 -46.07 82.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.211 -0.93 . . . . 0.0 109.432 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.654 ' O ' HG22 ' A' ' 7' ' ' VAL . 2.7 p 178.35 71.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -113.96 135.44 53.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.544 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -109.81 144.36 38.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.785 ' OG1' HD11 ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.521 HG12 ' HA ' ' A' ' 23' ' ' ALA . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.681 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.746 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.746 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.427 ' O ' ' N ' ' A' ' 42' ' ' LEU . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.738 HG12 HD21 ' A' ' 39' ' ' LEU . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.072 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.403 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.462 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.072 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 1.004 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.021 HG12 ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' O ' ' C ' ' A' ' 46' ' ' PHE . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.021 ' O ' HG12 ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.795 ' HA ' HD22 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.419 HG13 HG23 ' A' ' 41' ' ' VAL . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.535 ' C ' HD12 ' A' ' 54' ' ' LEU . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.542 HD13 HG22 ' A' ' 41' ' ' VAL . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.472 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.468 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.785 HD11 ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 53.46 66.86 4.16 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.251 -1.146 . . . . 0.0 109.416 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.91 149.38 65.86 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.724 2.283 . . . . 0.0 111.782 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 38.7 t -108.63 135.39 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.433 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -117.96 135.94 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.26 153.72 29.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.428 ' O ' HG23 ' A' ' 7' ' ' VAL . 29.4 m -68.29 128.79 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.386 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -113.5 149.3 34.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.508 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 -113.34 147.01 38.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.315 -0.866 . . . . 0.0 109.412 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.438 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.436 HG12 ' HA ' ' A' ' 23' ' ' ALA . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.476 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.471 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.661 ' CA ' HD12 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.74 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.492 HG12 HD21 ' A' ' 39' ' ' LEU . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.467 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.044 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 16.8 t-20 -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.41 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.044 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.984 HG22 HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.716 HD22 ' HB3' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.024 HG12 ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.482 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.024 ' O ' HG12 ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.716 ' HB3' HD22 ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.787 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.984 HD13 HG22 ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.476 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.531 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.44 ' HB3' ' HD2' ' A' ' 3' ' ' PRO . 16.5 mmt180 -125.31 161.69 48.52 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.208 -1.172 . . . . 0.0 109.503 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.44 ' HD2' ' HB3' ' A' ' 2' ' ' ARG . 50.3 Cg_endo -70.46 145.1 52.21 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.752 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 40.2 t -115.1 133.11 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.95 139.79 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.481 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -118.82 137.96 53.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.49 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.02 133.84 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -109.44 138.38 45.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.467 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.418 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 -110.93 155.2 23.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.46 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.64 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.75 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.529 HG12 HG12 ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.443 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.063 ' CD2' HG23 ' A' ' 32' ' ' VAL . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.541 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.681 HG22 HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.044 HG12 ' O ' ' A' ' 50' ' ' THR . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.638 HG22 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.638 ' CD1' HG22 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.478 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.044 ' O ' HG12 ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.501 HG12 HD11 ' A' ' 54' ' ' LEU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.942 ' C ' HD12 ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.942 HD12 ' C ' ' A' ' 53' ' ' GLU . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.462 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.874 ' CE1' HD11 ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.462 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.46 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.416 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 2' ' ' ARG . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.507 ' HB3' ' HD3' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -44.46 -59.76 3.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.257 -1.143 . . . . 0.0 109.511 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.507 ' HD3' ' HB3' ' A' ' 2' ' ' ARG . 52.1 Cg_endo -72.21 129.97 15.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.717 2.278 . . . . 0.0 111.75 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 42.1 t -130.96 141.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -0.844 . . . . 0.0 109.499 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 m -126.64 154.11 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.25 -0.906 . . . . 0.0 109.47 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.43 ' HB2' ' O ' ' A' ' 9' ' ' TYR . 95.3 mt-10 -57.19 138.13 55.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -0.929 . . . . 0.0 109.529 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.0 t -87.77 -11.93 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.85 . . . . 0.0 109.507 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.489 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . 91.9 m-20 -92.8 -72.16 0.61 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CE1' HG23 ' A' ' 59' ' ' VAL . 85.9 m-85 -124.34 148.64 47.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.409 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.462 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.737 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.575 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.574 ' C ' HG23 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.576 ' N ' HG23 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.478 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.4 OUTLIER -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.033 HD12 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.576 HG23 ' N ' ' A' ' 29' ' ' ILE . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.82 HD22 ' HB3' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.053 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.48 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.519 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . 1.053 ' O ' HG12 ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.82 ' HB3' HD22 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.788 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 ' C ' ' A' ' 53' ' ' GLU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.471 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.471 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.459 HG23 ' CE1' ' A' ' 9' ' ' TYR . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' NZ ' ' O ' ' A' ' 8' ' ' ASP . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.652 HG22 ' O ' ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ARG . . . . . 0.504 ' HB3' ' HD3' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -44.09 -61.23 2.14 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.504 ' HD3' ' HB3' ' A' ' 2' ' ' ARG . 51.3 Cg_endo -71.51 129.46 15.79 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.75 2.3 . . . . 0.0 111.84 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -139.84 153.16 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 7' ' ' VAL . 23.6 t -105.81 121.77 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.561 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -48.55 -29.05 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.164 -0.96 . . . . 0.0 109.409 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.557 ' H ' HG12 ' A' ' 5' ' ' VAL . 9.8 t -115.01 157.45 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.893 . . . . 0.0 109.508 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.422 ' O ' ' HE2' ' A' ' 61' ' ' LYS . 92.5 m-20 -90.3 -34.16 15.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.455 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.555 ' HB3' HD13 ' A' ' 29' ' ' ILE . 81.1 m-85 -142.82 153.63 43.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.243 -0.911 . . . . 0.0 109.518 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.415 ' HB3' HD12 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.717 HG11 ' HB2' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.784 ' CA ' HD12 ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.723 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.784 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.555 HD13 ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.116 ' CG2' HD12 ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.6 OUTLIER -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.116 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.516 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.642 HG22 HD12 ' A' ' 54' ' ' LEU . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.524 HD12 ' CA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.945 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.945 ' O ' HG12 ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.524 ' CA ' HD12 ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.559 HG13 HG23 ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.432 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.642 HD12 HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.489 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.489 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.422 ' HE2' ' O ' ' A' ' 8' ' ' ASP . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 38.0 mtp180 -123.96 78.0 58.36 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.267 -1.137 . . . . 0.0 109.522 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.0 150.11 66.31 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.655 2.237 . . . . 0.0 111.843 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.876 ' O ' HG12 ' A' ' 7' ' ' VAL . 39.3 t -104.82 139.37 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.222 -0.924 . . . . 0.0 109.461 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.404 ' H ' HG12 ' A' ' 5' ' ' VAL . 4.2 p -78.9 -22.45 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -0.862 . . . . 0.0 109.564 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.661 ' H ' HG12 ' A' ' 4' ' ' VAL . 36.9 mt-10 -61.16 -34.35 74.88 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.876 HG12 ' O ' ' A' ' 4' ' ' VAL . 12.7 p -58.05 -25.33 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.446 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -115.68 131.86 56.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.25 -0.907 . . . . 0.0 109.479 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.547 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 -107.75 159.71 16.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.291 -0.88 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' HB3' ' A' ' 27' ' ' ALA . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 22' ' ' PHE . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.471 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.756 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.79 ' C ' HG23 ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.79 HG23 ' C ' ' A' ' 23' ' ' ALA . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LEU . . . . . 0.756 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.61 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.55 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.562 ' N ' HG23 ' A' ' 41' ' ' VAL . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 30' ' ' SER . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.095 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.416 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 1.095 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.61 ' CG2' ' HB1' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.651 HD12 ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.969 HG12 ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.969 ' O ' HG12 ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.651 ' HA ' HD12 ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.498 ' HA ' HD23 ' A' ' 54' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.471 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.547 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ILE . . . . . 0.503 HG22 ' OXT' ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.653 HG11 HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.465 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.658 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.731 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.653 HD11 HG11 ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.728 HG23 HD12 ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.453 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.44 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.453 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 32' ' ' VAL . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.913 HG22 HD13 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.602 HD12 ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.01 HG12 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.461 ' O ' ' C ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.461 ' C ' ' O ' ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.01 ' O ' HG12 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.602 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.692 HG22 HD11 ' A' ' 54' ' ' LEU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.844 ' C ' HD12 ' A' ' 54' ' ' LEU . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.913 HD13 HG22 ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.483 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.483 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.465 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.52 HG12 ' HA ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.436 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.703 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.743 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.743 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.47 HG12 HD21 ' A' ' 39' ' ' LEU . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 HD12 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.431 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.431 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.063 HD12 HG23 ' A' ' 32' ' ' VAL . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.851 HG22 HD13 ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.621 HD12 ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.007 HG12 ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.007 ' O ' HG12 ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.621 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.544 ' C ' HD12 ' A' ' 54' ' ' LEU . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.851 HD13 HG22 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.517 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.44 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.457 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.667 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.741 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.741 HD23 ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.63 HG12 HD21 ' A' ' 39' ' ' LEU . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.077 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.41 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.077 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.795 HG22 HD13 ' A' ' 54' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 1.031 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.045 HG12 ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.045 ' O ' HG12 ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.869 ' HA ' HD22 ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.502 HG12 HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.703 ' C ' HD12 ' A' ' 54' ' ' LEU . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.795 HD13 HG22 ' A' ' 41' ' ' VAL . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.466 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.41 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.457 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.517 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.492 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.618 ' CA ' HD12 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.745 ' O ' HD23 ' A' ' 25' ' ' LEU . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.534 HD13 ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.086 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 6.1 t30 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.496 ' HG3' ' ND2' ' A' ' 33' ' ' ASN . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.406 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.086 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.493 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.788 HG22 HD12 ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.626 HD12 ' CA ' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.955 HG12 ' O ' ' A' ' 50' ' ' THR . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.463 ' O ' ' C ' ' A' ' 46' ' ' PHE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.955 ' O ' HG12 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.626 ' CA ' HD12 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.446 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 HG22 ' A' ' 41' ' ' VAL . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.48 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.406 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.48 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 5.6 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 121.301 0.572 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.785 ' OG1' HD11 ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.521 HG12 ' HA ' ' A' ' 23' ' ' ALA . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.681 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.746 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.746 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.427 ' O ' ' N ' ' A' ' 42' ' ' LEU . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.738 HG12 HD21 ' A' ' 39' ' ' LEU . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.072 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.403 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.462 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.072 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 1.004 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.021 HG12 ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' O ' ' C ' ' A' ' 46' ' ' PHE . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.021 ' O ' HG12 ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.795 ' HA ' HD22 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.419 HG13 HG23 ' A' ' 41' ' ' VAL . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.535 ' C ' HD12 ' A' ' 54' ' ' LEU . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.542 HD13 HG22 ' A' ' 41' ' ' VAL . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.472 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.468 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.785 HD11 ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.438 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.436 HG12 ' HA ' ' A' ' 23' ' ' ALA . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.476 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.471 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.661 ' CA ' HD12 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.74 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.492 HG12 HD21 ' A' ' 39' ' ' LEU . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.467 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.044 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.3 OUTLIER -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.41 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.044 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.984 HG22 HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.716 HD22 ' HB3' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.024 HG12 ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.482 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.024 ' O ' HG12 ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.716 ' HB3' HD22 ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.787 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.984 HD13 HG22 ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.476 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.531 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.418 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.46 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.64 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.75 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.529 HG12 HG12 ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.443 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.063 ' CD2' HG23 ' A' ' 32' ' ' VAL . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.541 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.681 ' CG2' HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.044 HG12 ' O ' ' A' ' 50' ' ' THR . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.638 HG22 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.638 ' CD1' HG22 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.478 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.044 ' O ' HG12 ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.501 HG12 HD11 ' A' ' 54' ' ' LEU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.942 ' C ' HD12 ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.942 HD12 ' C ' ' A' ' 53' ' ' GLU . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.462 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.874 ' CE1' HD11 ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.462 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.46 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.416 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CE1' HG23 ' A' ' 59' ' ' VAL . 85.9 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.462 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.737 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.575 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.574 ' C ' HG23 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.576 ' N ' HG23 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.478 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.033 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 39.6 t-20 -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.033 HD12 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.576 HG23 ' N ' ' A' ' 29' ' ' ILE . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.82 HD22 ' HB3' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.053 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.48 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.519 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 1.053 ' O ' HG12 ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.82 ' HB3' HD22 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.788 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 ' C ' ' A' ' 53' ' ' GLU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.471 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.471 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.459 HG23 ' CE1' ' A' ' 9' ' ' TYR . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.652 ' O ' HG22 ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.555 ' HB3' HD13 ' A' ' 29' ' ' ILE . 81.1 m-85 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.321 0.581 . . . . 0.0 109.518 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.415 ' HB3' HD12 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.717 HG11 ' HB2' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.784 ' CA ' HD12 ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.723 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.784 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.555 HD13 ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.116 ' CG2' HD12 ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 47.6 t-20 -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.116 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.516 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.642 HG22 HD12 ' A' ' 54' ' ' LEU . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.524 HD12 ' CA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.945 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.945 ' O ' HG12 ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.524 ' CA ' HD12 ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.559 HG13 HG23 ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.432 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.642 HD12 HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.489 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.489 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.547 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' HB3' ' A' ' 27' ' ' ALA . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 22' ' ' PHE . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' MET . . . . . 0.471 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.756 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.79 ' C ' HG23 ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.79 HG23 ' C ' ' A' ' 23' ' ' ALA . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LEU . . . . . 0.756 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.61 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.55 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.562 ' N ' HG23 ' A' ' 41' ' ' VAL . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 30' ' ' SER . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.095 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.416 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 1.095 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.61 ' CG2' ' HB1' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.651 HD12 ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.969 HG12 ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.969 ' O ' HG12 ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.651 ' HA ' HD12 ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 54' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.471 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.547 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ILE . . . . . 0.503 ' OXT' HG22 ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -122.41 94.09 48.03 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.161 . . . . 0.0 109.454 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.27 146.33 56.75 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.708 2.272 . . . . 0.0 111.749 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.534 HG12 ' H ' ' A' ' 6' ' ' GLU . 41.0 t -110.63 139.21 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.429 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.427 HG23 ' N ' ' A' ' 6' ' ' GLU . 15.2 m -59.63 -35.95 62.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.524 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.534 ' H ' HG12 ' A' ' 4' ' ' VAL . 82.5 tt0 -108.05 129.65 55.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.77 ' O ' HG22 ' A' ' 7' ' ' VAL . 7.4 p -132.64 33.51 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.274 -0.891 . . . . 0.0 109.427 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -119.29 136.1 54.4 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.9 . . . . 0.0 109.441 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.47 ' CD1' ' CD1' ' A' ' 56' ' ' PHE . 65.5 m-85 -102.68 149.21 24.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.323 -0.86 . . . . 0.0 109.487 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -134.48 173.8 11.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.7 t -86.56 147.22 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.304 -0.872 . . . . 0.0 109.42 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.27 -14.35 64.53 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -85.45 151.92 23.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.213 -1.169 . . . . 0.0 109.527 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.0 t -99.38 138.63 36.21 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.257 -0.902 . . . . 0.0 109.517 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.653 HG11 HD11 ' A' ' 29' ' ' ILE . 22.4 m -140.83 152.08 20.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.292 -0.88 . . . . 0.0 109.464 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.4 m -91.72 134.85 34.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.231 -0.918 . . . . 0.0 109.561 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 44.4 t -67.49 128.94 31.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.21 -0.931 . . . . 0.0 109.43 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.465 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 88.0 mtp -113.75 -19.58 11.48 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.596 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.8 t0 -134.82 146.54 49.38 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.219 -0.926 . . . . 0.0 109.534 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.58 -175.62 18.24 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.3 -20.17 21.48 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.67 2.246 . . . . 0.0 111.719 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.658 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.1 m-85 -96.24 9.89 39.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.308 -0.87 . . . . 0.0 109.63 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.57 132.33 6.29 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.184 -0.948 . . . . 0.0 109.821 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.731 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.0 m 80.1 47.86 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.423 -0.798 . . . . 0.0 109.346 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.731 HD23 ' O ' ' A' ' 24' ' ' THR . 58.2 mt -151.18 146.11 18.74 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.337 -0.852 . . . . 0.0 109.416 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.62 128.8 15.72 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.644 2.23 . . . . 0.0 111.766 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -140.45 161.64 37.23 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.269 -0.894 . . . . 0.0 109.444 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.5 m -120.08 125.43 48.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.305 -0.872 . . . . 0.0 109.402 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.653 HD11 HG11 ' A' ' 15' ' ' VAL . 97.6 mt -60.93 117.32 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.269 -0.894 . . . . 0.0 109.496 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t -103.3 -40.71 6.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.339 -0.851 . . . . 0.0 109.375 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.523 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -136.69 138.66 41.29 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.38 -0.825 . . . . 0.0 109.411 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.728 HG23 HD12 ' A' ' 39' ' ' LEU . 9.4 p -127.66 144.08 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.148 -0.97 . . . . 0.0 109.503 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.453 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 44.0 t-20 -125.1 84.63 2.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.59 -30.67 71.02 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.166 -0.959 . . . . 0.0 109.427 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 82.1 mt-10 -57.67 -45.71 85.23 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.308 -0.87 . . . . 0.0 109.6 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.44 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 87.2 mt-30 -100.81 15.88 26.93 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.254 -0.904 . . . . 0.0 109.48 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 53.4 39.07 29.36 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.453 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 80.8 mttt -121.3 149.76 42.43 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.728 HD12 HG23 ' A' ' 32' ' ' VAL . 0.7 OUTLIER -129.35 148.94 51.32 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.274 -0.891 . . . . 0.0 109.53 -179.927 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 31' ' ' GLU . 37.2 tttt -122.06 137.69 54.72 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.329 -0.857 . . . . 0.0 109.403 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.913 HG22 HD13 ' A' ' 54' ' ' LEU . 31.6 m -136.6 130.11 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.161 -0.962 . . . . 0.0 109.498 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.602 HD12 ' HA ' ' A' ' 51' ' ' PRO . 15.8 tp -84.99 141.5 30.28 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.831 . . . . 0.0 109.52 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.01 HG12 ' O ' ' A' ' 50' ' ' THR . 5.0 p -110.05 140.65 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.276 -0.89 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -104.21 129.49 51.99 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.223 -0.923 . . . . 0.0 109.503 -179.841 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.461 ' O ' ' C ' ' A' ' 46' ' ' PHE . 56.7 mt -140.83 149.04 21.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.285 -0.884 . . . . 0.0 109.299 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.461 ' C ' ' O ' ' A' ' 45' ' ' ILE . 14.8 m-30 -40.94 107.24 0.07 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.301 -0.875 . . . . 0.0 109.589 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.532 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 42.3 51.84 5.26 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.532 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 49.7 mtt85 -161.33 22.83 0.13 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.213 -1.169 . . . . 0.0 109.614 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.448 ' HG2' ' HA ' ' A' ' 44' ' ' SER . 79.2 mt-10 -46.55 119.58 2.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.219 -0.926 . . . . 0.0 109.376 179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.01 ' O ' HG12 ' A' ' 43' ' ' VAL . 98.2 m -134.2 122.49 16.15 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.209 -0.932 . . . . 0.0 109.604 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.602 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.69 136.98 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.581 2.187 . . . . 0.0 111.658 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.692 HG22 HD11 ' A' ' 54' ' ' LEU . 2.4 p -130.42 142.91 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.492 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.844 ' C ' HD12 ' A' ' 54' ' ' LEU . 85.2 tt0 -101.15 148.18 25.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.283 -0.886 . . . . 0.0 109.457 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.913 HD13 HG22 ' A' ' 41' ' ' VAL . 5.4 mp -149.11 174.84 11.9 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.241 -0.912 . . . . 0.0 109.462 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.483 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 17.0 p -105.42 158.57 16.56 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.254 -0.904 . . . . 0.0 109.445 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.47 ' CD1' ' CD1' ' A' ' 9' ' ' TYR . 52.2 m-85 -53.63 139.24 32.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.237 -0.915 . . . . 0.0 109.474 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.09 -24.66 29.07 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.483 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 28.5 mt-30 -75.37 -1.19 22.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.28 -1.129 . . . . 0.0 109.473 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.476 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 19.8 m -132.48 149.66 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.227 -0.92 . . . . 0.0 109.475 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.465 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.6 t -118.11 136.56 53.51 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.905 . . . . 0.0 109.478 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 96.3 mttt -73.32 152.61 40.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.216 -0.928 . . . . 0.0 109.462 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.2 mt . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.039 -0.982 . . . . 0.0 109.458 -179.962 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.52 ' N ' ' HD2' ' A' ' 3' ' ' PRO . 0.7 OUTLIER -45.05 -57.97 6.34 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.226 -1.161 . . . . 0.0 109.542 179.983 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.52 ' HD2' ' N ' ' A' ' 2' ' ' ARG . 51.6 Cg_endo -72.07 136.16 26.59 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 122.728 2.285 . . . . 0.0 111.792 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 13.3 m -113.46 34.0 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.156 -0.965 . . . . 0.0 109.545 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 52.9 t -140.85 153.68 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.512 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -61.59 146.19 49.67 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.285 -0.884 . . . . 0.0 109.556 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.6 t -125.07 140.02 49.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.964 . . . . 0.0 109.457 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -133.91 162.89 30.79 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.216 -0.928 . . . . 0.0 109.489 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -105.28 160.0 15.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.22 -0.925 . . . . 0.0 109.447 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -137.5 157.95 45.44 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.232 -0.918 . . . . 0.0 109.559 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.5 t -75.88 144.63 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.229 -0.92 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.83 -27.08 21.88 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 88.2 mt-10 -76.13 157.34 32.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.342 -1.093 . . . . 0.0 109.47 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.2 t -103.48 143.86 32.16 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.257 -0.902 . . . . 0.0 109.499 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.0 m -141.59 158.26 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.262 -0.899 . . . . 0.0 109.465 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 37.4 m -97.79 136.87 37.5 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.333 -0.854 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.52 HG12 ' HA ' ' A' ' 23' ' ' ALA . 43.9 t -65.35 125.99 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.247 -0.908 . . . . 0.0 109.45 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 95.0 mmm -110.85 -20.68 12.38 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.321 -0.862 . . . . 0.0 109.579 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 58' ' ' GLN . 14.9 t70 -136.46 147.28 47.11 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.633 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 109.96 -175.08 18.29 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.436 ' HG2' ' CD1' ' A' ' 22' ' ' PHE . 53.0 Cg_endo -72.98 -21.19 21.12 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.68 2.253 . . . . 0.0 111.758 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.703 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.6 m-85 -95.71 9.24 41.05 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.296 -0.877 . . . . 0.0 109.52 -179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -44.53 132.42 6.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.283 -0.885 . . . . 0.0 109.676 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.743 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.6 m 79.71 47.35 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.483 -0.76 . . . . 0.0 109.273 -179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.743 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.77 146.24 19.22 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.346 -0.846 . . . . 0.0 109.389 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.64 133.7 24.53 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.654 2.236 . . . . 0.0 111.704 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -145.49 160.65 41.29 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.909 . . . . 0.0 109.514 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.1 m -120.55 128.29 52.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.49 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.47 HG12 HD21 ' A' ' 39' ' ' LEU . 66.5 mt -64.02 115.69 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.408 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.473 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -100.16 -27.75 13.37 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.906 . . . . 0.0 109.412 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.491 ' O ' ' N ' ' A' ' 40' ' ' LYS . 99.5 mt-10 -156.38 142.68 18.3 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.279 -0.888 . . . . 0.0 109.426 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 HD12 ' A' ' 39' ' ' LEU . 9.8 p -128.25 145.13 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.912 . . . . 0.0 109.49 -179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -121.44 83.8 2.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -65.75 -24.87 67.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.261 -0.9 . . . . 0.0 109.423 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -61.65 -46.95 87.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.269 -0.894 . . . . 0.0 109.523 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.431 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 78.6 mt-30 -102.15 19.54 18.41 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.237 -0.914 . . . . 0.0 109.61 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 51.71 42.73 30.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.431 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 18.4 mttt -125.98 151.8 46.56 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.245 -0.91 . . . . 0.0 109.614 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.063 HD12 HG23 ' A' ' 32' ' ' VAL . 1.1 tp -129.96 149.73 51.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.393 -0.817 . . . . 0.0 109.36 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 24.8 tttm -120.65 136.58 54.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.256 -0.902 . . . . 0.0 109.697 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.851 HG22 HD13 ' A' ' 54' ' ' LEU . 31.3 m -135.3 142.66 39.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.411 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.621 HD12 ' HA ' ' A' ' 51' ' ' PRO . 40.8 tp -101.71 140.53 35.87 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.243 -0.91 . . . . 0.0 109.545 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.007 HG12 ' O ' ' A' ' 50' ' ' THR . 9.8 p -109.71 141.27 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.576 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -106.05 119.82 40.2 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.202 -0.936 . . . . 0.0 109.492 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' ARG . 34.2 mm -115.15 149.3 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.361 -0.837 . . . . 0.0 109.428 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.48 ' C ' ' O ' ' A' ' 45' ' ' ILE . 85.2 m-85 -39.53 107.64 0.07 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.409 -0.807 . . . . 0.0 109.595 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.522 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 53.09 41.28 60.17 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.522 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 26.1 mtt-85 -166.36 116.89 0.97 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.21 -1.17 . . . . 0.0 109.546 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -114.12 122.98 48.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.33 -0.857 . . . . 0.0 109.368 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.007 ' O ' HG12 ' A' ' 43' ' ' VAL . 27.3 m -129.74 112.8 17.63 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.315 -0.866 . . . . 0.0 109.698 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.621 ' HA ' HD12 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.26 142.52 41.61 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.665 2.243 . . . . 0.0 111.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 56.7 t -135.98 141.28 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.531 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.544 ' C ' HD12 ' A' ' 54' ' ' LEU . 84.6 tt0 -104.02 125.86 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.485 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.851 HD13 HG22 ' A' ' 41' ' ' VAL . 5.3 mp -123.78 174.68 7.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.412 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.472 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 56.7 p -106.75 160.27 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.395 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -55.62 133.86 50.75 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.2 -22.53 38.82 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.472 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 26.3 mt-30 -79.49 -0.15 32.03 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.345 -1.091 . . . . 0.0 109.405 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.7 m -131.07 148.53 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.189 -0.944 . . . . 0.0 109.423 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 31.0 t -119.01 140.03 50.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.178 -0.951 . . . . 0.0 109.477 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 32.4 mttt -77.33 144.71 37.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.922 . . . . 0.0 109.475 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 89.3 mt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.501 179.991 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 2.4 mtt85 -125.15 80.99 63.81 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.228 -1.16 . . . . 0.0 109.488 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.19 136.3 31.53 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.637 2.225 . . . . 0.0 111.808 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.738 HG22 ' H ' ' A' ' 6' ' ' GLU . 12.2 p -135.17 143.44 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.262 -0.899 . . . . 0.0 109.568 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.8 m -116.27 11.32 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.934 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.738 ' H ' HG22 ' A' ' 4' ' ' VAL . 97.1 mt-10 -64.91 137.58 57.84 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.198 -0.939 . . . . 0.0 109.458 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.688 ' O ' HG12 ' A' ' 7' ' ' VAL . 54.1 t -81.95 5.04 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.239 -0.913 . . . . 0.0 109.56 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 15.4 t0 -115.38 133.45 56.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.444 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.517 ' CD2' ' HE3' ' A' ' 61' ' ' LYS . 47.9 m-85 -96.82 169.88 9.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.287 -0.883 . . . . 0.0 109.533 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -123.06 151.95 41.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.484 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 41.7 t -71.73 147.07 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.159 -0.963 . . . . 0.0 109.513 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.81 -27.37 16.42 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.44 ' OE1' ' HA ' ' A' ' 13' ' ' GLU . 70.8 mm-40 -75.83 162.22 28.34 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.262 -1.14 . . . . 0.0 109.382 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 t -107.51 144.06 35.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.166 -0.959 . . . . 0.0 109.485 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 33.0 m -139.97 158.12 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.0 m -96.38 135.38 38.32 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.305 -0.872 . . . . 0.0 109.505 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 47.2 t -67.49 126.78 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.275 -0.89 . . . . 0.0 109.418 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.457 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 89.1 mtp -106.5 -20.02 13.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.245 -0.909 . . . . 0.0 109.58 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -134.9 144.24 47.39 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.214 -0.929 . . . . 0.0 109.597 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.07 -177.64 18.27 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -74.13 -18.88 20.7 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.686 2.257 . . . . 0.0 111.7 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.667 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.9 m-85 -92.54 8.84 37.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.571 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.67 132.54 4.93 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.2 -0.937 . . . . 0.0 109.639 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.741 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.3 m 80.73 45.39 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.55 -0.719 . . . . 0.0 109.175 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.741 HD23 ' O ' ' A' ' 24' ' ' THR . 57.0 mt -150.19 139.45 13.14 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.366 -0.834 . . . . 0.0 109.319 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.47 132.26 21.83 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.615 2.21 . . . . 0.0 111.86 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.22 161.59 35.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.261 -0.9 . . . . 0.0 109.393 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 85.8 m -117.33 127.26 53.89 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.244 -0.91 . . . . 0.0 109.445 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.63 HG12 HD21 ' A' ' 39' ' ' LEU . 74.6 mt -67.49 115.89 6.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.275 -0.891 . . . . 0.0 109.408 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 52.3 m -99.8 -23.19 15.06 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.484 ' O ' ' N ' ' A' ' 40' ' ' LYS . 81.4 tt0 -159.52 141.63 13.45 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.077 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.6 p -129.68 145.1 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.521 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 61.3 t30 -128.02 85.6 2.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.92 . . . . 0.0 109.564 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.08 -23.0 66.43 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.455 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -56.06 -46.45 78.94 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.216 -0.928 . . . . 0.0 109.465 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 82.6 mm-40 -107.4 18.1 21.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.525 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 57.3 mt-30 55.52 43.51 28.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.313 -0.867 . . . . 0.0 109.529 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 65.6 mttt -124.43 148.86 47.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.288 -0.882 . . . . 0.0 109.504 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.077 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -131.2 150.34 52.19 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.271 -0.893 . . . . 0.0 109.568 -179.833 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 17.5 tttm -118.46 134.71 54.85 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.341 -0.849 . . . . 0.0 109.415 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.795 HG22 HD13 ' A' ' 54' ' ' LEU . 28.1 m -133.9 155.18 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.168 -0.958 . . . . 0.0 109.657 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 1.031 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.1 tm? -105.97 137.18 44.32 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.276 -0.89 . . . . 0.0 109.223 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.045 HG12 ' O ' ' A' ' 50' ' ' THR . 5.5 p -105.11 139.92 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.168 -0.957 . . . . 0.0 109.382 179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.8 m -107.89 111.58 23.77 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.319 -0.863 . . . . 0.0 109.618 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' A' ' 48' ' ' ARG . 47.1 mt -108.52 149.09 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.351 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.455 ' C ' ' O ' ' A' ' 45' ' ' ILE . 87.2 m-85 -41.29 107.88 0.08 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.306 -0.871 . . . . 0.0 109.596 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.509 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 55.96 41.2 84.09 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.509 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 64.9 mtm-85 -166.38 121.1 1.14 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.219 -1.165 . . . . 0.0 109.584 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -120.52 121.02 37.53 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.252 -0.905 . . . . 0.0 109.289 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.045 ' O ' HG12 ' A' ' 43' ' ' VAL . 19.9 m -134.0 122.97 16.65 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.701 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.869 ' HA ' HD22 ' A' ' 42' ' ' LEU . 50.3 Cg_endo -70.43 138.62 36.09 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.502 HG12 HD11 ' A' ' 54' ' ' LEU . 46.2 t -125.71 140.1 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.703 ' C ' HD12 ' A' ' 54' ' ' LEU . 86.4 tt0 -97.39 128.82 44.52 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.795 HD13 HG22 ' A' ' 41' ' ' VAL . 5.8 mp -136.54 173.4 11.75 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.277 -0.889 . . . . 0.0 109.531 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.466 ' O ' ' HG3' ' A' ' 58' ' ' GLN . 5.8 p -110.28 165.94 11.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.172 -0.955 . . . . 0.0 109.422 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.41 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 98.8 m-85 -58.13 142.94 45.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.288 -0.882 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.75 -25.01 17.79 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.466 ' HG3' ' O ' ' A' ' 55' ' ' THR . 21.4 mt-30 -77.36 -1.11 28.32 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.278 -1.131 . . . . 0.0 109.54 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.4 m -131.07 146.26 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.546 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.457 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 36.7 t -111.05 135.61 51.3 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.335 -0.853 . . . . 0.0 109.414 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.517 ' HE3' ' CD2' ' A' ' 9' ' ' TYR . 58.1 mttp -71.68 148.8 46.11 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.339 -0.85 . . . . 0.0 109.486 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 75.8 mt . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.229 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 53.44 68.3 3.01 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.255 -1.144 . . . . 0.0 109.436 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -69.83 150.05 67.26 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.743 2.295 . . . . 0.0 111.771 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 41.9 t -110.18 136.46 46.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.312 -0.867 . . . . 0.0 109.422 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.3 m -131.03 162.72 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.275 -0.89 . . . . 0.0 109.514 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -86.6 148.32 25.54 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.6 t -104.94 124.46 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.272 -0.893 . . . . 0.0 109.466 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -134.1 160.52 37.54 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.568 ' CE1' ' CE ' ' A' ' 61' ' ' LYS . 88.5 m-85 -102.23 148.92 24.85 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.477 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 50.0 mt-10 -131.0 171.14 13.57 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.263 -0.898 . . . . 0.0 109.522 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.4 t -81.3 144.51 10.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.219 -0.925 . . . . 0.0 109.424 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.13 -9.12 65.29 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -91.43 153.26 19.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -1.141 . . . . 0.0 109.401 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.481 ' HA ' ' O ' ' A' ' 27' ' ' ALA . 28.1 t -106.78 143.15 35.28 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.507 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 34.8 m -138.15 160.81 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 46.8 m -98.71 133.11 43.5 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.258 -0.901 . . . . 0.0 109.535 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 40.9 t -67.12 126.67 27.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.276 -0.89 . . . . 0.0 109.386 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.492 ' HG3' ' HB2' ' A' ' 60' ' ' SER . 79.5 mmm -110.61 -19.48 12.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.898 . . . . 0.0 109.623 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -132.31 139.45 48.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.289 -0.882 . . . . 0.0 109.6 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.52 -176.8 17.17 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -73.72 -25.24 14.87 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.698 2.265 . . . . 0.0 111.788 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.618 ' CA ' HD12 ' A' ' 25' ' ' LEU . 20.4 m-85 -86.68 9.03 20.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.607 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.565 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -43.57 133.38 4.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.23 -0.919 . . . . 0.0 109.715 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.745 ' O ' HD23 ' A' ' 25' ' ' LEU . 0.4 OUTLIER 80.41 46.12 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.555 -0.716 . . . . 0.0 109.363 -179.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 24' ' ' THR . 63.4 mt -149.92 139.96 13.64 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.36 -0.838 . . . . 0.0 109.444 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.21 142.5 46.1 Favored 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.658 2.239 . . . . 0.0 111.763 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 14' ' ' SER . . . -145.4 160.37 41.66 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.353 -0.842 . . . . 0.0 109.417 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.8 m -118.1 125.7 50.81 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.26 -0.9 . . . . 0.0 109.575 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.534 HD13 ' HB3' ' A' ' 9' ' ' TYR . 73.2 mt -65.62 116.01 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.215 -0.928 . . . . 0.0 109.444 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.6 m -100.32 -28.36 13.0 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.195 -0.941 . . . . 0.0 109.592 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 96.6 mt-10 -150.36 142.39 23.97 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.198 -0.939 . . . . 0.0 109.612 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.086 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.3 p -130.79 133.29 63.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.28 -0.887 . . . . 0.0 109.406 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.515 ' N ' ' O ' ' A' ' 38' ' ' LYS . 6.1 t30 -115.97 85.56 2.31 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.199 -0.938 . . . . 0.0 109.588 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.49 -35.16 79.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.436 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -48.55 -46.23 38.68 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.477 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.496 ' HG3' ' ND2' ' A' ' 33' ' ' ASN . 32.5 mt-30 -107.67 14.61 25.46 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.446 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.406 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 76.8 mt-30 55.67 39.83 30.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.262 -0.899 . . . . 0.0 109.469 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASN . 39.5 mttp -118.51 118.9 32.96 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.518 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.086 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -102.87 150.92 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.493 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 52.0 mttt -123.77 139.49 53.93 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.33 -0.856 . . . . 0.0 109.639 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.788 HG22 HD12 ' A' ' 54' ' ' LEU . 35.5 m -135.58 144.78 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -0.897 . . . . 0.0 109.416 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.626 HD12 ' CA ' ' A' ' 51' ' ' PRO . 14.0 tp -104.42 140.52 37.81 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.483 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.955 HG12 ' O ' ' A' ' 50' ' ' THR . 7.9 p -111.36 142.27 24.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.286 -0.884 . . . . 0.0 109.425 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.81 125.46 50.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.498 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.463 ' O ' ' C ' ' A' ' 46' ' ' PHE . 18.4 mm -118.61 149.12 21.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.457 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.463 ' C ' ' O ' ' A' ' 45' ' ' ILE . 81.0 m-85 -40.69 108.32 0.09 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.338 -0.851 . . . . 0.0 109.609 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 52.99 52.67 38.07 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . . . . . . . . . 1.2 mtt180 176.33 125.88 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.251 -1.146 . . . . 0.0 109.514 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 12.4 mm-40 -119.13 128.07 53.93 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.217 -0.927 . . . . 0.0 109.329 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.955 ' O ' HG12 ' A' ' 43' ' ' VAL . 29.5 m -130.01 113.17 17.34 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.251 -0.906 . . . . 0.0 109.694 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.626 ' CA ' HD12 ' A' ' 42' ' ' LEU . 52.8 Cg_endo -72.24 145.94 44.73 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.681 2.254 . . . . 0.0 111.593 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.3 t -136.74 140.51 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.206 -0.934 . . . . 0.0 109.611 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.446 ' O ' ' HG ' ' A' ' 54' ' ' LEU . 94.5 mt-10 -100.83 137.24 39.48 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.311 -0.868 . . . . 0.0 109.504 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 HG22 ' A' ' 41' ' ' VAL . 1.5 mt -140.42 175.44 9.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.221 -0.925 . . . . 0.0 109.557 -179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.48 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.1 p -109.13 166.97 10.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.271 -0.893 . . . . 0.0 109.344 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.406 ' CE2' ' HA ' ' A' ' 37' ' ' GLN . 93.4 m-85 -63.05 130.74 46.0 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.901 . . . . 0.0 109.466 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 103.76 -25.58 26.11 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.48 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 5.6 mt-30 -75.59 -0.14 19.48 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.322 -1.104 . . . . 0.0 109.489 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 26.2 m -132.36 150.65 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.255 -0.903 . . . . 0.0 109.435 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB2' ' HG3' ' A' ' 18' ' ' MET . 22.9 t -118.15 137.41 52.99 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.898 . . . . 0.0 109.547 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.568 ' CE ' ' CE1' ' A' ' 9' ' ' TYR . 96.0 mttt -80.73 145.81 31.36 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.224 -0.922 . . . . 0.0 109.424 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 88.0 mt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.5 179.994 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.84 160.42 44.73 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.256 -1.143 . . . . 0.0 109.534 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.19 145.07 53.62 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.724 2.283 . . . . 0.0 111.768 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.5 m -128.52 161.27 37.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.288 -0.883 . . . . 0.0 109.486 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 19.5 m -130.02 144.5 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.212 -0.93 . . . . 0.0 109.467 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.6 mt-10 -57.07 -46.07 82.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.211 -0.93 . . . . 0.0 109.432 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.654 ' O ' HG22 ' A' ' 7' ' ' VAL . 2.7 p 178.35 71.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -113.96 135.44 53.99 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.282 -0.886 . . . . 0.0 109.544 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -109.81 144.36 38.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.228 -0.92 . . . . 0.0 109.468 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -129.25 162.56 27.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.0 t -81.05 146.49 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.172 -0.955 . . . . 0.0 109.515 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -17.91 58.18 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.418 ' HG2' ' N ' ' A' ' 14' ' ' SER . 81.9 tt0 -81.42 153.88 26.69 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.28 -1.13 . . . . 0.0 109.475 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 19.8 t -103.81 141.28 36.39 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.266 -0.897 . . . . 0.0 109.464 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 59' ' ' VAL . 19.4 m -138.9 163.36 27.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.26 -0.9 . . . . 0.0 109.482 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.785 ' OG1' HD11 ' A' ' 62' ' ' ILE . 42.9 m -101.72 135.29 43.51 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.913 . . . . 0.0 109.504 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.521 HG12 ' HA ' ' A' ' 23' ' ' ALA . 46.2 t -69.39 126.61 29.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.255 -0.903 . . . . 0.0 109.425 180.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.51 ' CE ' ' O ' ' A' ' 57' ' ' GLY . 55.4 mtm -109.17 -15.64 14.26 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.269 -0.895 . . . . 0.0 109.665 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.511 ' CB ' ' OE1' ' A' ' 58' ' ' GLN . 10.0 t0 -140.1 152.07 45.85 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 104.66 -176.2 22.95 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -73.37 -19.07 22.57 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.733 2.288 . . . . 0.0 111.74 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.681 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.7 m-85 -97.45 6.67 47.84 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.269 -0.894 . . . . 0.0 109.459 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.56 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.98 133.09 3.81 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.24 -0.912 . . . . 0.0 109.678 -179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.746 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 79.83 45.9 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.423 -0.798 . . . . 0.0 109.219 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.746 HD23 ' O ' ' A' ' 24' ' ' THR . 60.0 mt -150.28 138.71 12.51 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.389 -0.819 . . . . 0.0 109.416 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.47 129.35 16.69 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.649 2.233 . . . . 0.0 111.755 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -136.41 164.92 27.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.452 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.427 ' O ' ' N ' ' A' ' 42' ' ' LEU . 85.8 m -118.26 128.92 55.14 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.168 -0.957 . . . . 0.0 109.517 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.738 HG12 HD21 ' A' ' 39' ' ' LEU . 73.4 mt -70.21 116.48 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.96 . . . . 0.0 109.483 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 41.8 m -100.9 -41.29 6.89 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.2 -0.938 . . . . 0.0 109.516 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' O ' ' N ' ' A' ' 40' ' ' LYS . 64.8 tt0 -133.48 134.24 43.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.277 -0.889 . . . . 0.0 109.47 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.072 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.2 p -128.97 132.88 66.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.222 -0.924 . . . . 0.0 109.558 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 43.2 t-20 -112.31 88.68 2.87 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.188 -0.945 . . . . 0.0 109.531 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.25 -31.35 72.1 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.571 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -60.44 -42.7 96.64 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.264 -0.897 . . . . 0.0 109.559 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.403 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.0 mt-30 -102.28 13.89 33.41 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.942 . . . . 0.0 109.595 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 52.7 mt-30 53.04 41.05 32.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.219 -0.926 . . . . 0.0 109.445 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.462 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 45.7 mttp -120.73 148.5 43.87 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.332 -0.855 . . . . 0.0 109.316 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.072 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.2 tp -131.33 150.97 51.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.195 -0.94 . . . . 0.0 109.598 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.525 ' N ' ' O ' ' A' ' 31' ' ' GLU . 32.3 tttp -123.79 138.92 54.42 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.315 -0.866 . . . . 0.0 109.295 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.597 HG12 HG12 ' A' ' 29' ' ' ILE . 35.3 m -135.55 155.28 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.206 -0.934 . . . . 0.0 109.783 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 1.004 HD13 ' N ' ' A' ' 43' ' ' VAL . 2.5 tm? -105.71 136.79 44.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.403 -0.81 . . . . 0.0 109.196 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.021 HG12 ' O ' ' A' ' 50' ' ' THR . 8.8 p -105.07 139.66 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.147 -0.971 . . . . 0.0 109.298 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 73.2 m -105.88 116.92 32.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.284 -0.885 . . . . 0.0 109.603 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' O ' ' C ' ' A' ' 46' ' ' PHE . 35.7 mt -115.86 149.66 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.227 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.497 ' C ' ' O ' ' A' ' 45' ' ' ILE . 30.6 t80 -38.14 107.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.426 -0.796 . . . . 0.0 109.667 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.486 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 51.4 37.01 38.97 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 45' ' ' ILE . 22.4 mtp180 -158.79 116.18 2.82 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.195 -1.179 . . . . 0.0 109.621 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -114.79 121.72 44.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.254 -0.904 . . . . 0.0 109.226 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.021 ' O ' HG12 ' A' ' 43' ' ' VAL . 75.3 m -129.34 116.58 18.66 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.224 -0.923 . . . . 0.0 109.787 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.795 ' HA ' HD22 ' A' ' 42' ' ' LEU . 51.4 Cg_endo -71.06 135.53 27.59 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.706 2.27 . . . . 0.0 111.684 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.419 HG13 HG23 ' A' ' 41' ' ' VAL . 2.6 p -131.53 143.34 40.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.941 . . . . 0.0 109.545 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.535 ' C ' HD12 ' A' ' 54' ' ' LEU . 82.3 tt0 -102.48 141.63 34.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.369 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.542 HD13 HG22 ' A' ' 41' ' ' VAL . 5.6 mp -138.48 173.78 11.23 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.27 -0.894 . . . . 0.0 109.578 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.472 ' O ' ' HG2' ' A' ' 58' ' ' GLN . 21.0 p -103.4 153.59 20.32 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.348 -0.845 . . . . 0.0 109.464 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.438 ' CE1' ' HB2' ' A' ' 39' ' ' LEU . 6.7 m-30 -46.63 136.53 7.68 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.249 -0.907 . . . . 0.0 109.493 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.51 ' O ' ' CE ' ' A' ' 18' ' ' MET . . . 94.77 -19.13 55.44 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.511 ' OE1' ' CB ' ' A' ' 19' ' ' ASP . 51.2 mm-40 -75.33 -0.61 20.34 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.17 -1.194 . . . . 0.0 109.473 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 15' ' ' VAL . 23.4 m -135.42 158.44 40.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.251 -0.905 . . . . 0.0 109.47 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.468 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -123.57 140.6 52.84 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.197 -0.939 . . . . 0.0 109.531 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -83.17 148.84 27.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.928 . . . . 0.0 109.444 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.785 HD11 ' OG1' ' A' ' 16' ' ' THR . 97.9 mt . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.497 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 1.3 mtt-85 53.46 66.86 4.16 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.251 -1.146 . . . . 0.0 109.416 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.91 149.38 65.86 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.724 2.283 . . . . 0.0 111.782 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 38.7 t -108.63 135.39 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.223 -0.923 . . . . 0.0 109.433 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 44.7 t -117.96 135.94 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.322 -0.861 . . . . 0.0 109.491 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.26 153.72 29.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 7' ' ' VAL . 29.4 m -68.29 128.79 32.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.386 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -113.5 149.3 34.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.508 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.531 ' CE2' ' HE3' ' A' ' 61' ' ' LYS . 82.9 m-85 -113.34 147.01 38.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.315 -0.866 . . . . 0.0 109.412 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -125.52 154.95 41.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.233 -0.917 . . . . 0.0 109.557 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 45.2 t -69.73 144.63 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.428 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.29 -9.16 72.26 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.438 ' HG2' ' N ' ' A' ' 14' ' ' SER . 82.4 tt0 -88.22 155.34 19.8 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -1.131 . . . . 0.0 109.439 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 13' ' ' GLU . 11.8 t -103.0 139.84 38.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 24.1 m -142.13 151.63 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.21 -0.931 . . . . 0.0 109.453 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 38.9 m -90.4 138.32 31.64 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.165 -0.959 . . . . 0.0 109.513 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.436 HG12 ' HA ' ' A' ' 23' ' ' ALA . 40.5 t -80.05 137.34 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.494 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.476 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 61.1 mtm -123.57 -39.39 2.43 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.295 -0.878 . . . . 0.0 109.293 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.471 ' HB2' ' HB3' ' A' ' 58' ' ' GLN . 73.9 m-20 -97.15 128.85 44.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.302 -0.874 . . . . 0.0 109.485 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.36 -176.28 16.11 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.521 -1.431 . . . . 0.0 109.521 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -73.66 -23.39 16.96 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.725 2.283 . . . . 0.0 111.771 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.661 ' CA ' HD12 ' A' ' 25' ' ' LEU . 86.1 m-85 -88.34 9.51 23.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.298 -0.876 . . . . 0.0 109.633 -179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.556 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -46.69 133.21 10.7 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.677 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.74 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.7 m 79.61 47.78 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.582 -0.699 . . . . 0.0 109.366 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.74 HD23 ' O ' ' A' ' 24' ' ' THR . 59.0 mt -150.77 143.01 15.95 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.372 -0.83 . . . . 0.0 109.433 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -70.29 139.07 37.54 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.747 2.298 . . . . 0.0 111.765 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -147.19 160.1 42.85 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.322 -0.861 . . . . 0.0 109.508 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 58.5 m -119.05 125.31 49.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.255 -0.903 . . . . 0.0 109.457 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.492 HG12 HD21 ' A' ' 39' ' ' LEU . 76.3 mt -63.06 131.25 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.467 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 28.1 t -117.45 -28.58 6.05 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.432 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.47 ' HB2' ' HD2' ' A' ' 40' ' ' LYS . 86.9 mt-10 -151.07 142.16 23.11 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.257 -0.902 . . . . 0.0 109.498 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.044 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.7 p -131.03 140.53 48.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.239 -0.913 . . . . 0.0 109.522 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.519 ' N ' ' O ' ' A' ' 38' ' ' LYS . 0.3 OUTLIER -116.49 88.75 2.96 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.237 -0.914 . . . . 0.0 109.505 -179.902 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -33.35 75.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.333 -0.854 . . . . 0.0 109.481 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -61.45 -47.84 83.88 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.41 ' O ' ' HG3' ' A' ' 38' ' ' LYS . 85.6 mt-30 -99.57 12.17 37.19 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.256 -0.903 . . . . 0.0 109.507 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 51.07 38.84 21.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.226 -0.921 . . . . 0.0 109.401 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' A' ' 33' ' ' ASN . 73.2 mttt -118.14 120.53 37.99 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -0.874 . . . . 0.0 109.496 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.044 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -103.25 151.56 22.52 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.888 . . . . 0.0 109.466 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 27.6 mttm -122.51 138.59 54.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.336 -0.853 . . . . 0.0 109.629 -179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.984 HG22 HD13 ' A' ' 54' ' ' LEU . 23.7 m -135.56 151.5 30.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.206 -0.934 . . . . 0.0 109.397 179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.716 HD22 ' HB3' ' A' ' 51' ' ' PRO . 15.6 mt -106.5 141.84 37.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.155 -0.965 . . . . 0.0 109.591 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.024 HG12 ' O ' ' A' ' 50' ' ' THR . 6.1 p -109.09 140.32 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.283 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.47 114.36 28.32 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.253 -0.905 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 38.4 mm -108.16 147.93 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.26 -0.9 . . . . 0.0 109.33 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -46.77 108.47 0.14 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.691 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.482 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 62.48 43.84 98.45 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.528 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 39.7 ttt180 177.64 128.71 0.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -1.158 . . . . 0.0 109.556 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.39 128.18 46.63 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.291 -0.88 . . . . 0.0 109.31 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.024 ' O ' HG12 ' A' ' 43' ' ' VAL . 16.5 m -133.71 119.14 14.81 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.229 -0.919 . . . . 0.0 109.734 -179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.716 ' HB3' HD22 ' A' ' 42' ' ' LEU . 50.0 Cg_endo -70.45 145.09 52.16 Favored 'Trans proline' 0 C--O 1.214 -0.717 0 C-N-CA 122.706 2.27 . . . . 0.0 111.688 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 48.9 t -133.91 140.93 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.59 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.787 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.0 tt0 -97.3 134.45 40.58 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.372 -0.83 . . . . 0.0 109.412 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.984 HD13 HG22 ' A' ' 41' ' ' VAL . 5.5 mp -139.13 175.41 9.58 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 109.539 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 3.8 p -112.44 169.27 9.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.196 -0.94 . . . . 0.0 109.365 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -62.6 133.4 54.84 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.147 -0.971 . . . . 0.0 109.382 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 100.27 -27.37 20.7 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 16.1 mt-30 -73.78 -1.62 20.08 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.261 -1.14 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.0 m -133.58 152.16 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.167 -0.958 . . . . 0.0 109.44 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.476 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 34.4 t -121.68 137.07 54.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.185 -0.947 . . . . 0.0 109.52 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.531 ' HE3' ' CE2' ' A' ' 9' ' ' TYR . 18.6 mttt -74.56 149.61 40.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.283 -0.885 . . . . 0.0 109.442 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 91.0 mt . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 117.946 -1.026 . . . . 0.0 109.484 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.44 ' HB3' ' HD2' ' A' ' 3' ' ' PRO . 16.5 mmt180 -125.31 161.69 48.52 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.208 -1.172 . . . . 0.0 109.503 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.44 ' HD2' ' HB3' ' A' ' 2' ' ' ARG . 50.3 Cg_endo -70.46 145.1 52.21 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.714 2.276 . . . . 0.0 111.752 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 40.2 t -115.1 133.11 62.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.169 -0.957 . . . . 0.0 109.477 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.2 m -131.95 139.79 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.298 -0.876 . . . . 0.0 109.481 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -118.82 137.96 53.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.251 -0.906 . . . . 0.0 109.49 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.02 133.84 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.23 -0.919 . . . . 0.0 109.486 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 44.5 t0 -109.44 138.38 45.89 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.166 -0.959 . . . . 0.0 109.467 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.418 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-85 -110.93 155.2 23.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.245 -0.909 . . . . 0.0 109.493 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -127.45 159.43 34.54 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.215 -0.928 . . . . 0.0 109.463 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 50.0 t -74.92 145.32 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.523 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.85 -11.3 71.22 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -84.96 153.1 23.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.213 -1.169 . . . . 0.0 109.53 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 9.0 t -99.87 139.0 36.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.442 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 32.8 m -138.04 162.51 31.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.259 -0.9 . . . . 0.0 109.48 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 91.6 m -102.49 132.81 48.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.214 -0.928 . . . . 0.0 109.505 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 45.1 t -65.27 125.38 22.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.294 -0.879 . . . . 0.0 109.441 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.46 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 91.1 mtp -109.31 -18.86 13.48 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.23 -0.919 . . . . 0.0 109.589 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -135.1 145.74 48.18 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.601 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.0 -176.6 19.31 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -73.8 -24.45 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.697 2.265 . . . . 0.0 111.718 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.64 ' CA ' HD12 ' A' ' 25' ' ' LEU . 96.2 m-85 -88.85 7.13 35.8 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.201 -0.937 . . . . 0.0 109.585 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.558 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.09 132.73 3.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.145 -0.972 . . . . 0.0 109.804 -179.679 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.75 ' O ' HD23 ' A' ' 25' ' ' LEU . 2.6 m 80.28 46.46 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.563 -0.711 . . . . 0.0 109.394 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 24' ' ' THR . 60.8 mt -150.67 141.71 14.92 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.315 -0.866 . . . . 0.0 109.375 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -70.33 132.24 22.04 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.641 2.228 . . . . 0.0 111.863 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -137.47 161.67 35.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.845 . . . . 0.0 109.428 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.3 m -119.15 122.28 41.67 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.91 . . . . 0.0 109.618 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.529 HG12 HG12 ' A' ' 41' ' ' VAL . 28.7 mt -60.87 114.76 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.327 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.7 m -98.91 -24.46 14.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.598 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB3' ' CB ' ' A' ' 40' ' ' LYS . 72.5 tt0 -151.07 147.87 27.63 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.146 -0.971 . . . . 0.0 109.666 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.063 HG23 ' CD2' ' A' ' 39' ' ' LEU . 9.9 p -121.33 135.89 60.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.257 -0.902 . . . . 0.0 109.556 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -121.52 62.8 0.91 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.238 -0.914 . . . . 0.0 109.382 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -55.35 -35.01 64.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.444 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -51.18 -48.53 61.9 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.353 -0.842 . . . . 0.0 109.431 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -100.43 19.98 15.73 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.897 . . . . 0.0 109.546 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.443 ' HA ' ' CE2' ' A' ' 56' ' ' PHE . 73.9 mt-30 52.54 44.3 30.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.192 -0.942 . . . . 0.0 109.593 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 55' ' ' THR . 23.7 mttt -133.1 158.04 43.78 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.511 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.063 ' CD2' HG23 ' A' ' 32' ' ' VAL . 3.6 mt -134.09 154.67 51.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.247 -0.908 . . . . 0.0 109.473 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.541 ' CB ' ' HB3' ' A' ' 31' ' ' GLU . 16.6 tttm -113.71 130.72 56.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.427 -0.795 . . . . 0.0 109.117 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.681 ' CG2' HD13 ' A' ' 54' ' ' LEU . 17.9 m -129.92 136.26 59.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.152 -0.968 . . . . 0.0 109.671 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 51' ' ' PRO . 13.0 tp -92.12 138.66 31.35 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.321 -0.862 . . . . 0.0 109.264 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.044 HG12 ' O ' ' A' ' 50' ' ' THR . 4.8 p -112.55 140.74 30.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 65.3 m -104.49 122.53 45.73 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.265 -0.897 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.638 HG22 ' CD1' ' A' ' 46' ' ' PHE . 47.4 mt -120.04 149.27 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.269 -0.894 . . . . 0.0 109.337 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.638 ' CD1' HG22 ' A' ' 45' ' ' ILE . 30.3 p90 -39.54 109.4 0.11 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 109.604 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.478 ' O ' ' HG3' ' A' ' 48' ' ' ARG . . . 50.35 39.12 35.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.478 ' O ' ' HB ' ' A' ' 45' ' ' ILE . 7.8 mtp-105 -161.31 118.54 2.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.256 -1.143 . . . . 0.0 109.554 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -116.71 123.42 47.18 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.318 -0.864 . . . . 0.0 109.271 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.044 ' O ' HG12 ' A' ' 43' ' ' VAL . 52.2 m -137.19 121.01 11.98 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.794 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 51.1 Cg_endo -71.14 144.75 47.56 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.669 2.246 . . . . 0.0 111.575 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.501 HG12 HD11 ' A' ' 54' ' ' LEU . 57.0 t -133.9 141.28 44.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.59 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.942 ' C ' HD12 ' A' ' 54' ' ' LEU . 83.9 tt0 -102.29 139.13 38.31 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.224 -0.923 . . . . 0.0 109.567 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.942 HD12 ' C ' ' A' ' 53' ' ' GLU . 6.6 mp -139.76 174.69 10.26 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.179 -0.951 . . . . 0.0 109.409 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.462 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 1.6 p -105.77 158.56 16.65 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.148 -0.97 . . . . 0.0 109.546 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.874 ' CE1' HD11 ' A' ' 39' ' ' LEU . 96.8 m-85 -54.93 132.82 47.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.221 -0.924 . . . . 0.0 109.391 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 101.55 -25.02 29.57 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.462 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 34.0 mt-30 -76.62 -0.31 22.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.362 -1.081 . . . . 0.0 109.469 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 15.6 m -132.69 149.76 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.46 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 10.1 t -125.04 137.74 54.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.237 -0.914 . . . . 0.0 109.406 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.416 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 96.4 mttt -77.79 149.45 34.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.224 -0.923 . . . . 0.0 109.486 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 27.1 pt . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.484 179.992 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.405 ' O ' ' C ' ' A' ' 2' ' ' ARG . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.507 ' HB3' ' HD3' ' A' ' 3' ' ' PRO . 0.0 OUTLIER -44.46 -59.76 3.59 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.257 -1.143 . . . . 0.0 109.511 179.94 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.507 ' HD3' ' HB3' ' A' ' 2' ' ' ARG . 52.1 Cg_endo -72.21 129.97 15.77 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.717 2.278 . . . . 0.0 111.75 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 42.1 t -130.96 141.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.35 -0.844 . . . . 0.0 109.499 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.3 m -126.64 154.11 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.25 -0.906 . . . . 0.0 109.47 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.43 ' HB2' ' O ' ' A' ' 9' ' ' TYR . 95.3 mt-10 -57.19 138.13 55.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.213 -0.929 . . . . 0.0 109.529 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.0 t -87.77 -11.93 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.85 . . . . 0.0 109.507 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.489 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . 91.9 m-20 -92.8 -72.16 0.61 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.376 -0.828 . . . . 0.0 109.425 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.459 ' CE1' HG23 ' A' ' 59' ' ' VAL . 85.9 m-85 -124.34 148.64 47.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.409 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -131.2 147.25 52.58 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.281 -0.887 . . . . 0.0 109.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 52.9 t -61.43 141.57 17.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.467 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.18 -13.02 67.62 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -84.67 154.0 22.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.24 -1.153 . . . . 0.0 109.473 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.9 t -99.99 140.46 34.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.314 -0.866 . . . . 0.0 109.46 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -138.76 167.56 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.266 -0.896 . . . . 0.0 109.521 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.6 m -109.73 136.29 49.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.243 -0.91 . . . . 0.0 109.481 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.489 HG11 ' HB2' ' A' ' 22' ' ' PHE . 26.8 t -66.74 124.37 21.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.298 -0.876 . . . . 0.0 109.525 179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.462 ' HG3' ' OG ' ' A' ' 60' ' ' SER . 60.9 mmm -113.62 -21.9 10.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.231 -0.918 . . . . 0.0 109.522 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 37.6 t0 -126.87 131.3 51.21 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.45 -175.92 15.95 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -73.35 -21.24 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.673 2.249 . . . . 0.0 111.74 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.596 ' CA ' HD12 ' A' ' 25' ' ' LEU . 89.5 m-85 -91.51 12.45 20.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 109.505 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.566 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -47.33 134.1 11.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.686 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.737 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.2 m 80.19 46.7 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.43 -0.794 . . . . 0.0 109.326 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 24' ' ' THR . 61.3 mt -150.51 148.89 24.94 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.34 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.0 143.61 50.21 Favored 'Trans proline' 0 C--O 1.217 -0.565 0 C-N-CA 122.623 2.215 . . . . 0.0 111.855 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.575 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -146.58 148.03 31.71 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -0.909 . . . . 0.0 109.424 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.574 ' C ' HG23 ' A' ' 41' ' ' VAL . 53.2 m -113.84 117.39 31.3 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 109.171 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.576 ' N ' HG23 ' A' ' 41' ' ' VAL . 33.9 mt -59.58 124.56 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.273 -0.892 . . . . 0.0 109.65 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.478 ' HB2' ' HG ' ' A' ' 42' ' ' LEU . 11.0 t -114.27 -23.08 9.61 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.258 -0.901 . . . . 0.0 109.311 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 98.2 mt-10 -153.01 137.87 17.1 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.499 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.033 ' CG2' HD12 ' A' ' 39' ' ' LEU . 7.0 p -130.42 139.13 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.317 -0.864 . . . . 0.0 109.439 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.496 ' N ' ' O ' ' A' ' 38' ' ' LYS . 39.6 t-20 -115.88 85.97 2.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.21 -30.96 71.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -61.67 -45.29 94.64 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.895 . . . . 0.0 109.44 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -101.64 9.87 40.68 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.283 -0.886 . . . . 0.0 109.626 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 55.78 36.96 28.27 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.198 -0.939 . . . . 0.0 109.417 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASN . 23.7 mttp -118.54 121.21 39.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.266 -0.896 . . . . 0.0 109.559 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.033 HD12 ' CG2' ' A' ' 32' ' ' VAL . 0.9 OUTLIER -103.13 151.44 22.57 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -0.888 . . . . 0.0 109.659 -179.858 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.49 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 55.4 mttp -125.78 141.52 51.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 109.524 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.576 HG23 ' N ' ' A' ' 29' ' ' ILE . 2.3 p -142.48 147.14 21.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.263 -0.898 . . . . 0.0 109.426 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.82 HD22 ' HB3' ' A' ' 51' ' ' PRO . 14.2 mt -100.55 141.81 32.89 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.333 -0.854 . . . . 0.0 109.573 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.053 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -104.33 143.2 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.427 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 55.7 m -107.36 110.65 22.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.255 -0.903 . . . . 0.0 109.398 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 48' ' ' ARG . 64.2 mt -103.21 148.63 8.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.216 -0.928 . . . . 0.0 109.419 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.414 ' C ' ' O ' ' A' ' 45' ' ' ILE . 74.3 m-85 -44.34 108.13 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.264 -0.898 . . . . 0.0 109.617 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.48 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 59.44 46.62 93.61 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.519 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 12.6 ttt85 177.41 129.23 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.249 -1.148 . . . . 0.0 109.501 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 82.2 mt-10 -122.42 125.68 46.37 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.26 -0.9 . . . . 0.0 109.465 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 1.053 ' O ' HG12 ' A' ' 43' ' ' VAL . 20.6 m -128.42 116.6 19.89 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.239 -0.913 . . . . 0.0 109.658 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.82 ' HB3' HD22 ' A' ' 42' ' ' LEU . 51.3 Cg_endo -70.47 144.05 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.682 2.255 . . . . 0.0 111.792 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 49.9 t -139.33 141.36 35.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.544 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.788 ' C ' HD12 ' A' ' 54' ' ' LEU . 87.2 mt-10 -96.92 148.26 23.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.479 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.788 HD12 ' C ' ' A' ' 53' ' ' GLU . 5.1 mp -149.46 174.77 12.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.584 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.471 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 6.9 p -109.64 164.61 12.38 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.273 -0.892 . . . . 0.0 109.33 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -59.13 138.38 57.59 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.143 -0.973 . . . . 0.0 109.343 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 96.72 -24.73 29.58 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.471 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 33.7 mt-30 -75.33 -0.17 18.82 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.309 -1.112 . . . . 0.0 109.479 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.459 HG23 ' CE1' ' A' ' 9' ' ' TYR . 22.2 m -131.61 148.68 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.257 -0.902 . . . . 0.0 109.47 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.462 ' OG ' ' HG3' ' A' ' 18' ' ' MET . 68.4 m -118.19 137.34 53.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.173 -0.954 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' NZ ' ' O ' ' A' ' 8' ' ' ASP . 85.3 mttt -76.36 151.12 36.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.47 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.652 ' O ' HG22 ' A' ' 62' ' ' ILE . 88.6 mt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.496 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . 0.504 ' HB3' ' HD3' ' A' ' 3' ' ' PRO . 0.1 OUTLIER -44.09 -61.23 2.14 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.504 ' HD3' ' HB3' ' A' ' 2' ' ' ARG . 51.3 Cg_endo -71.51 129.46 15.79 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.75 2.3 . . . . 0.0 111.84 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 16.0 m -139.84 153.16 22.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.557 HG12 ' H ' ' A' ' 7' ' ' VAL . 23.6 t -105.81 121.77 58.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.262 -0.899 . . . . 0.0 109.561 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -48.55 -29.05 3.82 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.164 -0.96 . . . . 0.0 109.409 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.557 ' H ' HG12 ' A' ' 5' ' ' VAL . 9.8 t -115.01 157.45 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.272 -0.893 . . . . 0.0 109.508 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.422 ' O ' ' HE2' ' A' ' 61' ' ' LYS . 92.5 m-20 -90.3 -34.16 15.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.259 -0.9 . . . . 0.0 109.455 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.555 ' HB3' HD13 ' A' ' 29' ' ' ILE . 81.1 m-85 -142.82 153.63 43.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.243 -0.911 . . . . 0.0 109.518 -179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -130.86 160.9 33.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.195 -0.941 . . . . 0.0 109.504 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -73.52 139.73 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.223 -0.923 . . . . 0.0 109.485 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.82 -9.36 61.93 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.415 ' HB3' HD12 ' A' ' 29' ' ' ILE . 82.7 tt0 -90.26 150.84 21.78 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.193 -1.181 . . . . 0.0 109.616 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.7 t -104.88 143.49 33.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.233 -0.917 . . . . 0.0 109.472 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.8 m -142.94 154.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 56.9 m -85.26 123.79 31.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.445 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.717 HG11 ' HB2' ' A' ' 22' ' ' PHE . 63.0 t -63.63 134.15 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.254 -0.904 . . . . 0.0 109.333 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 53.1 mmm -125.02 -38.04 2.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.218 -0.926 . . . . 0.0 109.493 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . 0.47 ' CB ' ' HB3' ' A' ' 58' ' ' GLN . 12.3 t0 -98.05 122.1 40.77 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.312 -0.868 . . . . 0.0 109.576 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.16 -177.16 16.32 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -74.1 -17.92 21.6 Favored 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.721 2.281 . . . . 0.0 111.835 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.784 ' CA ' HD12 ' A' ' 25' ' ' LEU . 94.2 m-85 -87.69 4.47 43.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.284 -0.885 . . . . 0.0 109.75 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 24' ' ' THR . . . -42.36 131.84 3.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -0.946 . . . . 0.0 109.748 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.723 ' O ' HD23 ' A' ' 25' ' ' LEU . 1.9 m 78.72 47.64 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.527 -0.733 . . . . 0.0 109.228 -179.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.784 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.4 mt -149.84 141.78 15.22 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.444 -0.785 . . . . 0.0 109.486 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.97 122.36 8.98 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.629 2.219 . . . . 0.0 111.819 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -129.61 160.29 33.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.431 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 90.3 m -119.49 125.87 49.92 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.153 -0.967 . . . . 0.0 109.489 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.555 HD13 ' HB3' ' A' ' 9' ' ' TYR . 62.9 mt -63.02 122.46 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.262 -0.899 . . . . 0.0 109.399 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 34.3 t -107.05 -35.11 6.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.211 -0.93 . . . . 0.0 109.482 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.486 ' O ' ' N ' ' A' ' 40' ' ' LYS . 61.8 mm-40 -145.78 142.76 29.2 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.178 -0.951 . . . . 0.0 109.647 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.116 ' CG2' HD12 ' A' ' 39' ' ' LEU . 5.3 p -132.81 137.44 53.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -0.871 . . . . 0.0 109.383 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.517 ' N ' ' O ' ' A' ' 38' ' ' LYS . 47.6 t-20 -116.98 88.68 2.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.18 -38.45 88.08 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 89.0 mt-10 -53.1 -48.85 67.48 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.454 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 92.6 mt-30 -97.9 6.01 48.27 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 67.5 mt-30 58.34 36.34 25.46 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 109.406 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASN . 15.3 mttp -116.35 119.75 36.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -0.917 . . . . 0.0 109.445 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.116 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.0 OUTLIER -102.99 150.06 23.93 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.917 . . . . 0.0 109.558 -179.875 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.516 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 29.1 mttt -124.14 139.52 53.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.319 -0.863 . . . . 0.0 109.564 -179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.642 HG22 HD12 ' A' ' 54' ' ' LEU . 35.2 m -133.05 132.5 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.524 HD12 ' CA ' ' A' ' 51' ' ' PRO . 9.7 tp -99.11 137.5 37.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.193 -0.942 . . . . 0.0 109.414 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.945 HG12 ' O ' ' A' ' 50' ' ' THR . 8.7 p -105.72 141.59 20.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.301 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 47.8 m -107.29 110.25 22.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.151 -0.968 . . . . 0.0 109.519 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 48' ' ' ARG . 31.6 mm -103.4 148.86 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.273 -0.892 . . . . 0.0 109.321 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.438 ' C ' ' O ' ' A' ' 45' ' ' ILE . 54.2 m-85 -42.72 109.57 0.14 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.325 -0.859 . . . . 0.0 109.634 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 48' ' ' ARG . . . 56.44 47.31 84.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 45' ' ' ILE . 20.2 ttt180 177.85 125.8 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.241 -1.153 . . . . 0.0 109.511 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -120.24 126.23 50.1 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.315 -0.866 . . . . 0.0 109.342 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.945 ' O ' HG12 ' A' ' 43' ' ' VAL . 33.8 m -124.21 108.09 29.91 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.916 . . . . 0.0 109.662 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.524 ' CA ' HD12 ' A' ' 42' ' ' LEU . 53.6 Cg_endo -73.0 148.29 44.85 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.687 2.258 . . . . 0.0 111.695 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.559 HG13 HG23 ' A' ' 41' ' ' VAL . 2.7 p -141.59 142.34 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.242 -0.911 . . . . 0.0 109.631 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.432 ' C ' ' HG ' ' A' ' 54' ' ' LEU . 75.4 tt0 -101.42 131.24 47.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 109.438 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.642 HD12 HG22 ' A' ' 41' ' ' VAL . 4.5 mt -134.29 175.3 9.63 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.239 -0.913 . . . . 0.0 109.544 180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.489 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 19.1 p -111.28 166.41 11.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.127 -0.983 . . . . 0.0 109.423 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -61.44 130.0 43.9 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.161 -0.962 . . . . 0.0 109.438 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.48 -25.63 25.26 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 -179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.489 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 19.3 mt-30 -76.02 0.48 18.44 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.32 -1.106 . . . . 0.0 109.552 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.7 m -132.45 152.01 35.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 71.9 m -109.68 143.55 39.28 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.258 -0.901 . . . . 0.0 109.509 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.422 ' HE2' ' O ' ' A' ' 8' ' ' ASP . 76.7 mttt -81.32 147.14 30.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.473 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . . . . . . . . . 82.3 mt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.958 -1.02 . . . . 0.0 109.496 -179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ARG . . . . . . . . . . . . . 38.0 mtp180 -123.96 78.0 58.36 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.267 -1.137 . . . . 0.0 109.522 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -70.0 150.11 66.31 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.655 2.237 . . . . 0.0 111.843 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.876 ' O ' HG12 ' A' ' 7' ' ' VAL . 39.3 t -104.82 139.37 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.222 -0.924 . . . . 0.0 109.461 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.404 ' H ' HG12 ' A' ' 5' ' ' VAL . 4.2 p -78.9 -22.45 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.321 -0.862 . . . . 0.0 109.564 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.661 ' H ' HG12 ' A' ' 4' ' ' VAL . 36.9 mt-10 -61.16 -34.35 74.88 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.275 -0.89 . . . . 0.0 109.511 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.876 HG12 ' O ' ' A' ' 4' ' ' VAL . 12.7 p -58.05 -25.33 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.446 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -115.68 131.86 56.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.25 -0.907 . . . . 0.0 109.479 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.547 ' CE1' ' HE3' ' A' ' 61' ' ' LYS . 78.0 m-85 -107.75 159.71 16.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.291 -0.88 . . . . 0.0 109.398 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -121.41 147.93 45.07 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.22 -0.925 . . . . 0.0 109.551 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.2 t -67.35 142.16 16.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.267 -0.895 . . . . 0.0 109.449 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.95 -12.82 68.09 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -84.12 152.47 24.3 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.167 -1.196 . . . . 0.0 109.564 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 12.4 t -95.06 147.53 23.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.362 -0.836 . . . . 0.0 109.451 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.528 HG23 ' HB3' ' A' ' 27' ' ' ALA . 28.6 m -146.35 160.23 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.285 -0.884 . . . . 0.0 109.437 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.3 m -105.54 134.45 48.64 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.265 -0.897 . . . . 0.0 109.506 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.553 HG11 ' HB2' ' A' ' 22' ' ' PHE . 44.6 t -67.71 129.06 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.238 -0.914 . . . . 0.0 109.354 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.471 ' SD ' ' HB2' ' A' ' 60' ' ' SER . 55.5 mtm -118.0 -17.85 9.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.256 -0.902 . . . . 0.0 109.578 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 31.4 t0 -129.09 134.4 48.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.155 -0.966 . . . . 0.0 109.618 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 113.95 -175.26 16.19 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -73.14 -13.49 25.91 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.789 2.326 . . . . 0.0 111.775 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.756 ' CA ' HD12 ' A' ' 25' ' ' LEU . 97.4 m-85 -98.53 6.33 47.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.551 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.79 ' C ' HG23 ' A' ' 24' ' ' THR . . . -42.4 134.04 3.09 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.851 -179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.79 HG23 ' C ' ' A' ' 23' ' ' ALA . 1.2 p 76.32 48.77 0.07 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.481 -0.762 . . . . 0.0 109.248 -179.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LEU . . . . . 0.756 HD12 ' CA ' ' A' ' 22' ' ' PHE . 64.3 mt -150.48 151.7 31.45 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.534 -0.729 . . . . 0.0 109.226 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -69.85 144.25 52.96 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.642 2.228 . . . . 0.0 111.759 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.61 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -147.37 145.07 29.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.298 -0.876 . . . . 0.0 109.591 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.55 ' C ' HG23 ' A' ' 41' ' ' VAL . 34.7 m -113.38 115.37 27.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.896 . . . . 0.0 109.233 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.562 ' N ' HG23 ' A' ' 41' ' ' VAL . 65.2 mt -59.39 114.28 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.264 -0.897 . . . . 0.0 109.694 -179.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 31' ' ' GLU . 1.9 m -98.33 -25.38 14.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.317 -0.864 . . . . 0.0 109.293 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.479 ' HG3' ' O ' ' A' ' 30' ' ' SER . 97.8 mt-10 -157.96 144.05 17.36 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.278 -0.889 . . . . 0.0 109.422 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.095 ' CG2' HD12 ' A' ' 39' ' ' LEU . 8.0 p -128.6 144.76 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.238 -0.913 . . . . 0.0 109.533 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.416 ' HB3' ' HB2' ' A' ' 38' ' ' LYS . 49.0 t30 -123.94 81.91 1.97 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -66.26 -27.82 68.24 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.457 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -52.64 -45.79 66.81 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 61.5 mm-40 -106.92 19.36 20.57 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.207 -0.933 . . . . 0.0 109.482 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 13.7 mt-30 55.6 41.56 30.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.196 -0.94 . . . . 0.0 109.383 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.416 ' HB2' ' HB3' ' A' ' 33' ' ' ASN . 20.7 mttp -124.08 149.83 45.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.224 -0.923 . . . . 0.0 109.467 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 1.095 HD12 ' CG2' ' A' ' 32' ' ' VAL . 1.1 tp -128.99 148.95 51.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.132 -0.98 . . . . 0.0 109.402 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.54 ' N ' ' HG ' ' A' ' 39' ' ' LEU . 45.2 tttp -117.96 134.9 54.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.581 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.61 ' CG2' ' HB1' ' A' ' 27' ' ' ALA . 3.3 p -137.89 141.06 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.294 -0.879 . . . . 0.0 109.366 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.651 HD12 ' HA ' ' A' ' 51' ' ' PRO . 26.7 tp -102.35 140.87 36.05 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.244 -0.91 . . . . 0.0 109.625 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.969 HG12 ' O ' ' A' ' 50' ' ' THR . 7.1 p -106.47 143.06 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.261 -0.9 . . . . 0.0 109.338 179.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 61.2 m -109.02 109.96 21.11 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.248 -0.908 . . . . 0.0 109.702 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' O ' ' A' ' 48' ' ' ARG . 53.1 mt -104.71 149.0 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.337 -0.852 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.478 ' C ' ' O ' ' A' ' 45' ' ' ILE . 71.6 m-85 -40.11 107.55 0.07 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.336 -0.852 . . . . 0.0 109.522 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 48' ' ' ARG . . . 54.71 40.72 72.28 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 47' ' ' GLY . 10.7 mtt180 -165.99 113.68 0.92 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.283 -1.127 . . . . 0.0 109.607 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 87.4 mt-10 -110.68 120.2 41.63 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.163 -0.961 . . . . 0.0 109.294 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.969 ' O ' HG12 ' A' ' 43' ' ' VAL . 94.9 m -127.13 112.12 21.64 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.241 -0.912 . . . . 0.0 109.724 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.651 ' HA ' HD12 ' A' ' 42' ' ' LEU . 52.0 Cg_endo -71.87 145.61 45.94 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.636 2.224 . . . . 0.0 111.68 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.1 p -140.93 140.78 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.178 -0.951 . . . . 0.0 109.403 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -94.74 126.0 39.76 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.291 -0.881 . . . . 0.0 109.515 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 54' ' ' LEU . 17.4 mt -123.7 171.35 9.66 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.305 -0.872 . . . . 0.0 109.559 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.482 ' OG1' ' HG3' ' A' ' 58' ' ' GLN . 4.0 p -112.24 160.62 17.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.245 -0.91 . . . . 0.0 109.453 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -57.08 121.35 9.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.309 -0.869 . . . . 0.0 109.361 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 113.05 -26.84 10.11 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLN . . . . . 0.482 ' HG3' ' OG1' ' A' ' 55' ' ' THR . 27.8 mt-30 -76.76 -0.19 22.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.251 -1.146 . . . . 0.0 109.408 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.1 m -134.83 155.39 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.239 -0.913 . . . . 0.0 109.419 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.471 ' HB2' ' SD ' ' A' ' 18' ' ' MET . 13.3 t -127.59 139.61 52.64 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.946 . . . . 0.0 109.616 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.547 ' HE3' ' CE1' ' A' ' 9' ' ' TYR . 81.1 mttt -79.78 150.54 30.73 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.278 -0.889 . . . . 0.0 109.411 -179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ILE . . . . . 0.503 ' OXT' HG22 ' A' ' 62' ' ' ILE . 86.9 mt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.521 179.962 . . . . . . . . 1 1 . 1 stop_ save_